Conditions: Depressive Disorder, Major
Keywords: Depression
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 363
Healthy volunteers: no

Brief summary:
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).

Detailed description:

Arms:
arm 1: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) arm 2: Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks) arm 3: Placebo (prefilled syringe, weekly IV administration)

Interventions: intervention 1: Rapastinel intervention 2: Placebo
Intervention descriptions: intervention 1: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks) intervention 2: Placebo (prefilled syringe, weekly IV administration)

Protocol document:
Prot_000.pdf: 
NCT03614156 
 
Study ID: RAP‐MD‐33 
 
 
 
Title: A Randomized, Double‐blind, Placebo‐controlled, Multicenter Study of Rapastinel in the 
Prevention of Relapse in Patients with Major Depressive Disorder 
 
Protocol Date: 02 May 2018 
 
 


Naurex, Inc.
1
RAP-MD-33 Protocol Final
02 May 2018
1.0
TITLE PAGE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel 
in the Prevention of Relapse in Patients with Major Depressive Disorder
RAP-MD-33
(3106-333-008)
IND # 136,870
Original Protocol Date:
02 May 2018
Sponsor:
Naurex Inc., an indirect 
subsidiary of Allergan, plc
5 Giralda Farms
Madison, NJ 07940
Allergan, Ltd.
Marlow International 
The Parkway
Marlow Buckinghamshire
SL7 1YL, UK
Confidentiality Statement
This document is the property of Allergan, plc and may not—in full or part—be passed 
on, reproduced, published, distributed, or submitted to any regulatory authority without 
the express written permission of Allergan, plc.


Naurex, Inc.
2
RAP-MD-33 Protocol Final
02 May 2018
2.0
SYNOPSIS AND SCHEDULE OF EVALUATIONS
CLINICAL STUDY SYNOPSIS: Study RAP-MD-33
Study Number
RAP-MD-33 (3106-333-008)
Title of Study
A Randomized, Double-blind, Placebo-controlled, 
Multicenter Study of Rapastinel in the Prevention of Relapse 
in Patients with Major Depressive Disorder
Study Centers (Country)
Approximately 145 study centers
Development Phase
3
Objective
To evaluate the efficacy, safety, and tolerability of rapastinel 
relative to placebo in the prevention of relapse in patients 
with major depressive disorder (MDD)
Methodology
Multicenter, randomized-withdrawal, parallel-group, 
placebo-controlled, maintenance study in patients with 
MDD.
For patients enrolling from RAP-MD-30, RAP-MD-31, or 
RAP-MD-32 (lead-in studies), the final visit from that study 
(ie, Visit 9) will serve as Visit 1 in Study RAP-MD-33.
This study comprises the following periods:

An 8- to 16-week, open-label treatment period (OLTP) 
during which patients will receive intravenous (IV) 
rapastinel (450 mg or 225 mg) once weekly to identify 
stable responders. Individual treatment duration in the 
period will be at least 8 weeks and up to 16 weeks to 
accommodate variability among patients and adequately 
identify stable responders (patients treated for a 
minimum of 8 weeks and meet OLTP stability 
assessment criteria)

A 52-week, double-blind, randomized-withdrawal period 
during which stable responders from the open-label 
period will be randomized (1:1:1) to 1 of 3 double-blind 
treatment arms: 
o
Rapastinel weekly (IV, 450 mg or 225 mg)
o
Rapastinel clinically driven schedule (IV, 450 
mg or 225 mg, variable interval, placebo on 
intervening weeks)
o
Placebo weekly (IV)

A 2-week safety follow-up period.
Number of Patients
Approximately 1400 planned to be enrolled in the OLTP; 
approximately 600 planned to be randomized during the 
double-blind treatment period (DBTP)


Naurex, Inc.
3
RAP-MD-33 Protocol Final
02 May 2018
Diagnosis and Main Criteria for 
Inclusion

Completion of RAP-MD-30, RAP-MD-31, or RAP-MD-
32

Male or female outpatients, 18 to 75 years of age (at 
time of entry to lead-in study)
 
 
 
Test Product, Dosage, and Mode 
of Administration
OLTP: Patients will receive IV rapastinel (450 mg or 225 
mg weekly) once weekly. The dose assigned in the OLTP 
will be based on the dose received in the lead-in study such 
that those who received placebo, vortioxetine, or 450 mg or 
900 mg rapastinel in the lead-in study will be assigned 450
mg rapastinel, while those who received 225 mg rapastinel 
in the lead-in study will be assigned 225 mg rapastinel.  
DBTP: The study center investigator will submit the clinical 
assessment to the interactive web response system (IWRS) at 
each visit in a blinded manner.  Depending on the assigned 
treatment arm, the IWRS will dispense the following 
treatments:

Rapastinel weekly arm: rapastinel (450 mg or 225
mg, based on dose patient received in OLTP), 
regardless of clinical assessment

Rapastinel clinically-driven schedule arm: 
o
“Clinically unstable”: rapastinel (450 mg or 
225 mg, based on dose patient received in 
OLTP)
o
“Clinically stable”: placebo IV 

Placebo weekly arm: placebo IV at each visit, 
regardless of clinical assessment
Duration of Participation
An 8- to 16-week OLTP; a DBTP with a maximum duration 
of 52 weeks; and a 2-week Safety Follow-up Period.  Each 
randomized patient will be treated until relapse criteria are 
met or until he/she has completed 52 weeks of double-blind 
treatment or discontinued for other reasons.
Reference Therapy, Dosage, and 
Mode of Administration
OLTP: N/A  
DBTP: Placebo (IV, weekly)


Naurex, Inc.
4
RAP-MD-33 Protocol Final
02 May 2018
Criteria for Evaluation
Primary Endpoint
Time to first relapse during 52 weeks of the DBTP, defined 
as the number of days from the randomization date to the 
relapse date. Relapse during the DBTP is defined as meeting 
1 or more of the following criteria within 52 weeks of 
randomization:
o
Montgomery-Åsberg Depression Rating Scale
(MADRS) total score ≥ 18 at 2 consecutive visits, 
or
o
A ≥ 2 increase in Clinical Global Impressions-
Severity (CGI-S) score compared with that obtained 
at randomization, or
o
Risk of suicide as determined by the investigator, or
o
Need for hospitalization due to worsening of 
depression as determined by the investigator, or
o
Need for alternative treatment of depressive 
symptoms as determined by the investigator
 
 
 
 
 
 
 
 
 


Naurex, Inc.
5
RAP-MD-33 Protocol Final
02 May 2018
Statistical Methods
The primary efficacy analysis will compare the time to 
relapse between placebo and rapastinel treatment groups in
the respective time-frame (within the 52 weeks of the DBTP) 
using the log-rank test and the Double-blind Modified 
Intent-To-Treat (mITT) Population. Estimates of the hazard 
ratio and 95% confidence intervals will be based on the Cox 
proportional hazards model with treatment group as an 
explanatory variable. The cumulative distribution function of 
time to relapse will be characterized by the Kaplan-Meier 
curves.
All safety parameters will be analyzed descriptively for the 
Open-label Safety Population and the Double-blind Safety 
Population.
The Open-label Safety Population will consist of all 
screened patients who receive at least 1 dose of 
investigational product (IP) during the OLTP.
The Double-blind Safety Population will consist of all 
randomized patients who receive at least 1 dose of double-
blind IP during the DBTP of the study.
The Double-blind mITT Population will consist of all 
patients in the Double-blind Safety Population who had at 
least 1 postrandomization assessment of MADRS or CGI-S
during the DBTP of the study.


Naurex, Inc.
6
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
7
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
8
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
9
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
10
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
11
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
12
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
13
RAP-MD-33 Protocol Final
02 May 2018
3.0
TABLE OF CONTENTS
1.0
TITLE PAGE....................................................................................................................................1
2.0
SYNOPSIS AND SCHEDULE OF EVALUATIONS .....................................................................2
3.0
TABLE OF CONTENTS................................................................................................................13
LIST OF FIGURES ........................................................................................................................15
4.0
LIST OF ABBREVIATIONS.........................................................................................................16
5.0
ETHICAL CONSIDERATIONS....................................................................................................19
5.1
Institutional Review Board and Independent Ethics Committee ......................................19
5.2
Ethical Conduct of the Study............................................................................................19
5.3
Patient Information and Informed Consent.......................................................................20
6.0
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ......................................21
7.0
INTRODUCTION ..........................................................................................................................22
8.0
STUDY OBJECTIVES...................................................................................................................26
9.0
INVESTIGATIONAL PLAN .........................................................................................................28
9.1
Overall Study Design and Plan: Description ....................................................................28
9.1.1
Open-label Treatment Period..............................................................................28
9.1.2
Double-Blind Treatment Period .........................................................................29
9.1.3
Safety Follow-up Period.....................................................................................31
9.2
Discussion of Study Design, Including the Choice of Control Groups.............................32
9.3
Selection of Study Population...........................................................................................34
9.3.1
Inclusion Criteria................................................................................................34
9.3.2
Exclusion Criteria...............................................................................................35
9.3.3
Removal of Patients from Therapy or Assessment.............................................36
9.3.3.1
Criteria for Required Removal of Patients from Therapy or 
Assessment.......................................................................................37
9.3.4
Patient Replacement Procedures ........................................................................37
9.4
Treatments ........................................................................................................................38
9.4.1
Treatments Administered ...................................................................................38
9.4.2
Identity of Investigational Products....................................................................39
9.4.3
Handling of Investigational Products .................................................................40
9.4.4
Method of Assigning Patients to Treatment Groups ..........................................40
9.4.5
Selection of Dosages in the Study ......................................................................40
9.4.6
Selection and Timing of Dose for Each Patient..................................................41
9.4.6.1
Open-label Treatment Period............................................................41
9.4.6.2
Double-blind Treatment Period ........................................................41
9.4.6.3
Safety Follow-up Period...................................................................42
9.4.7
Blinding..............................................................................................................42
9.4.8
Unblinding..........................................................................................................42
9.4.9
Prior and Concomitant Therapy .........................................................................43
9.4.10
Other Restrictions...............................................................................................44


Naurex, Inc.
14
RAP-MD-33 Protocol Final
02 May 2018
9.4.10.1
Alcohol .............................................................................................44
9.4.10.2
Contraception ...................................................................................44
9.4.11
Monitoring Treatment Compliance ....................................................................45
9.4.12
Treatment After Discontinuation........................................................................45
9.5
Efficacy and Safety Assessments......................................................................................46
9.5.1
Diagnostic and Efficacy Assessments ................................................................46
9.5.1.1
Diagnostic Assessments ...................................................................46
9.5.1.2
Efficacy Assessments .......................................................................46
9.6
Data Quality Assurance ....................................................................................................77
9.6.1
Data Monitoring .................................................................................................77
9.6.2
Data Recording and Documentation...................................................................77
9.7
Statistical Methods and Determination of Sample Size....................................................78
9.7.1
Analysis Populations ..........................................................................................78
9.7.1.1
Open-label Safety Population...........................................................78
9.7.1.2
Open-label Modified Intent-to-Treat Population..............................78
9.7.1.3
Double-Blind Safety Population.......................................................78
9.7.1.4
Double-Blind Modified Intent-to-Treat Population..........................79
9.7.1.5
Pharmacokinetic Population.............................................................79
9.7.2
Patient Disposition .............................................................................................79
9.7.3
Demographics and Other Baseline Characteristics.............................................79
9.7.4
Extent of Exposure and Treatment Compliance.................................................79
9.7.4.1
Extent of Exposure ...........................................................................79
9.7.4.2
Prior and Concomitant Medication...................................................80
9.7.4.3
Measurement of Treatment Compliance...........................................80
9.7.5
Efficacy Analyses...............................................................................................80
9.7.5.1
Primary Efficacy Analyses ...............................................................81
9.7.6
Safety Analyses ..................................................................................................82
9.7.6.1
Adverse Events.................................................................................82


Naurex, Inc.
15
RAP-MD-33 Protocol Final
02 May 2018
9.7.9
Interim Analysis .................................................................................................86
9.7.10
Determination of Sample Size............................................................................87
9.7.11
Statistical Software.............................................................................................87
9.8
Data and Safety Monitoring Board...................................................................................87
9.9
Changes in the Conduct of the Study or Planned Analyses ..............................................87
9.10
Protocol Deviations ..........................................................................................................88
10.0
STUDY SPONSORSHIP................................................................................................................89
10.1
Study Termination ............................................................................................................89
10.2
Reporting and Publication ................................................................................................89
11.0
INVESTIGATOR OBLIGATIONS................................................................................................90
11.1
Documentation..................................................................................................................90
11.2
Performance......................................................................................................................91
11.3
Use of Investigational Materials.......................................................................................91
11.4
Case Report Forms ...........................................................................................................91
11.5
Retention and Review of Records.....................................................................................91
11.6
Patient Confidentiality......................................................................................................92
12.0
INVESTIGATOR’S STATEMENT ...............................................................................................93
13.0
APPENDICES ................................................................................................................................94
Appendix I.
Elements of Informed Consent...........................................................................94
Appendix II.
Contact Information............................................................................................96
Appendix IV.
Scales and Questionnaires ................................................................................102
14.0
LITERATURE CITED .................................................................................................................103
LIST OF FIGURES
Figure 9.1.3–1.
Study Design ......................................................................................................32


Naurex, Inc.
16
RAP-MD-33 Protocol Final
02 May 2018
4.0
LIST OF ABBREVIATIONS
ADT
antidepressant therapy
AE
adverse event
ALT
alanine aminotransferase 
AST
aspartate aminotransferase
β-hCG
β-human chorionic gonadotropin
BP
blood pressure
CFR
Code of Federal Regulations
CI
confidence interval
CNS
central nervous system
CSFQ
Changes in Sexual Functioning Questionnaire 
DALYs
disability adjusted life years
DBTP
double-blind treatment period
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSMB
Data and Safety Monitoring Board
DSST
Digit Symbol Substitution Test 
EC
Ethics Committee
ECG
electrocardiogram, electrocardiographic
eCRF
electronic case report form
EDC
electronic data capture
 
ET
early termination
FDA
Food and Drug Administration
FR
Federal Register
GCP
good clinical practice
HIPAA
Health Insurance Portability and Accountability Act of 1996


Naurex, Inc.
17
RAP-MD-33 Protocol Final
02 May 2018
ICF
informed consent form
ICH
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IND
Investigational New Drug (application)
IP
investigational product
IRB
Institutional Review Board
ITT
Intent-to-Treat
IUD
intrauterine device
IV
intravenous
IWRS
Interactive Web Response System
MADRS
Montgomery-Åsberg Depression Rating Scale
MDD
major depressive disorder
MMRM
mixed-effect model for repeated measures
NEAE
newly emergent adverse event
NMDAR 
N-methyl-D-aspartate receptor
PCS
potentially clinically significant
PID
patient identification
QTc
QT interval corrected for heart rate
QTcB
QT interval corrected for heart rate using the Bazett formula 
(QTcB = QT/[RR]½)
QTcF
QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/[RR]⅓)
SAE
serious adverse event
SAP
Statistical Analysis Plan
 
SD
standard deviation
SDMT
Symbol Digit Modalities Test
SIGMA
Structured Interview Guide for the MADRS
SNRI
selective serotonin and norepinephrine reuptake inhibitor
SOC
system organ class


Naurex, Inc.
18
RAP-MD-33 Protocol Final
02 May 2018
SSRI
selective serotonin reuptake inhibitor
T3
triiodothyronine
T4
thyroxine 
TEAE
treatment-emergent adverse event
TSH
thyroid-stimulating hormone 
UDS
urine drug screen
ULN
upper limit of normal


Naurex, Inc.
19
RAP-MD-33 Protocol Final
02 May 2018
5.0
ETHICAL CONSIDERATIONS
5.1
INSTITUTIONAL REVIEW BOARD AND INDEPENDENT 
ETHICS COMMITTEE
United States
Approval by the Institutional Review Board (IRB) before the start of the study will be the 
responsibility of the investigator. A copy of the approval letter will be supplied to the 
sponsor, along with a roster of IRB members or the US Department of Health and Human 
Services general assurance number. During the course of the study, the investigator will 
provide timely and accurate reports to the IRB on the progress of the study, at intervals 
not exceeding 1 year (or as appropriate), and will notify the IRB of serious adverse events 
(SAEs) or other significant safety findings. The study protocol, informed consent form 
(ICF), information sheet, advertisements (as applicable), and amendments (if any) will be 
approved by the IRBs at the study centers in conformance with the US CFR, Title 21, 
Part 56.
Outside the United States
This study will be carried out in full compliance with the guidelines of the independent
ethics committee (EC) or IRB (as applicable) and/or government agencies as applicable 
for each respective country as well as the European Union Clinical Trial Directive 
(Directive 2001/20/EC), where applicable. Before the study begins, the study centers will 
require approval from an EC/IRB and government agency. During the course of the 
study, the sponsor or authorized representative will provide timely and accurate reports to 
the EC/IRB on the progress of the study, at intervals not exceeding 1 year (or as 
appropriate) and will notify the EC/IRB of SAEs or other significant safety findings. The 
study protocol, ICF, information sheet, advertisements (if applicable), and amendments 
(if any) will be approved by the EC/IRB at the study centers in conformance with CFR, 
Title 21, Part 56, the European Union Clinical Trial Directive (Directive 2001/20/EC), 
and local regulations.
5.2
ETHICAL CONDUCT OF THE STUDY
This clinical study will be conducted in accordance with the ethical principles that have 
their origins in the Declaration of Helsinki.
This clinical study will comply with the ICH Guidance on General Considerations for 
Clinical Trials (ICH-E8; 62 FR 66113, 17 Dec 1997) and GCP (ICH-E6; 62 FR 25692, 
09 May 1997), as well as Part 312 of the US CFR.


Naurex, Inc.
20
RAP-MD-33 Protocol Final
02 May 2018
5.3
PATIENT INFORMATION AND INFORMED CONSENT
After being given an explanation of the study and before participating in any study 
procedures, each patient must provide written informed consent that meets the 
requirements of 21 CFR 50 (where applicable), local regulations, ICH guidelines, HIPAA 
requirements, where applicable, and the IRB/EC or study center.
Each patient will read and sign an ICF and/or other authorization form as per local 
regulations; each patient will be made aware that he or she may withdraw from the study 
at any time.
The ICF contains all the elements of informed consent listed in Appendix I of this 
protocol. Signed copies of the ICF and the HIPAA or other locally applicable form will 
be given to the patient, and both documents will be placed in the investigator’s study 
files.


Naurex, Inc.
21
RAP-MD-33 Protocol Final
02 May 2018
6.0
INVESTIGATORS AND STUDY ADMINISTRATIVE 
STRUCTURE
This study will be performed at approximately 145 study centers in North America, 
Europe, and Asia.
The investigator is responsible for ensuring that the investigation is conducted according 
to the signed investigator statement, the investigational plan, GCP guidelines, and 
applicable regulations; for protecting the rights, safety, and welfare of patients under the 
investigator’s care; and for the control of investigational products under investigation. An 
investigator shall obtain the informed consent for each patient prior to the patient 
enrolling in the study and/or prior to participating in any study-related activity. 
The investigator at each study center must meet his or her obligations to the patients, 
ethics committee, sponsor, and regulatory authorities by maintaining oversight and 
control of the study’s conduct and the study staff. It is the responsibility of the 
investigator to ensure that any and all delegated duties be assigned to qualified staff by 
education, experience, and licensure (in accordance with local regulations) and that the 
investigator oversight is documented and assessment of staff capabilities and 
performance is consistent with the study investigational plan. The investigator at each 
study center will be responsible for the management of the study, including maintaining 
the study file and the patient records, corresponding with the IRB/EC (where applicable), 
and completing the electronic case report forms (eCRFs).


Naurex, Inc.
22
RAP-MD-33 Protocol Final
02 May 2018
7.0
INTRODUCTION
Disease Burden of Major Depressive Disorder
Major depressive disorder (MDD) is a highly disabling, serious condition which is 
associated with significant morbidity and mortality. MDD manifests as a major 
depressive episode (which may be singular or recurrent) in which the affected individual 
experiences 1) depressed mood, or 2) loss of interest or pleasure (as well as other 
symptoms) for most of the day, nearly every day, for at least 2 weeks. MDD affects 
approximately 14.8 million American adults, or about 6.7% of the US population 18 
years of age and older, in a given year (Kessler et al, 2005). Worldwide, about 15% of the 
adult population is at lifetime risk of developing MDD (Kessler et al, 1994).
Depression may cause serious, long-lasting symptoms and often disrupts a person’s 
ability to perform routine tasks. In 2000, unipolar depressive disorders were by far the 
leading cause (11.9%) of worldwide years of life lived with disability (World Health 
Organization, 2001), and the total economic burden of treating depression in the United 
States was $83.1 billion, with workplace costs, including missed days and lack of 
productivity due to illness, accounting for most of the total economic burden (62%). 
Other economic burdens in 2000 included $26.1 billion (31%) for treatment costs and 
$5.4 billion (7%) for suicide-related costs (Greenberg et al, 2003). 
MDD is a leading cause of disability in the United States (Murray et al, 2013). Moreover, 
MDD is known to be a significant risk factor for suicide and ischemic heart disease, as it 
accounted for 16 million of the disability adjusted life years (DALYs) associated with 
suicide and 4 million of the DALYs associated with ischemic heart disease. Research has 
shown that untreated depression has both a functional (social and work role) as well as a 
neuroanatomical (hippocampal shrinkage) effect on the patient (Videbech and Ravnkilde, 
2004). Given the disease burden and link to suicidality as well as increased mortality with 
other comorbid conditions, MDD is a serious and life-threatening condition which is a 
leading cause of disability in the world.


Naurex, Inc.
23
RAP-MD-33 Protocol Final
02 May 2018
Selective Serotonin Reuptake Inhibitors and Selective Serotonin Norepinephrine 
Reuptake Inhibitors in Major Depressive Disorder
Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs) currently represent the first line of treatment 
of depression in the United States. Unfortunately, a large number of patients do not 
experience therapeutic benefit from these first-line agents (Rosenzweig-Lipson et al, 
2007). Lack of sufficient response to adequate treatment remains a critical problem in the 
management of patients with MDD. Up to two-thirds of patients treated with first-line 
antidepressant monotherapy do not reach full remission, and as many as a third become 
treatment resistant (Fava and Davidson, 1996; Trivedi et al, 2006). Not achieving 
remission has been shown to be predictive of poorer psychosocial functioning, higher 
rates of relapse, and higher rates of rehospitalization (McIntyre and Donovan, 2004). The 
results of the STAR*D study suggest that with successive failures of treatment, patients 
are less and less likely to respond to subsequent treatment, and those who do respond are 
more likely to relapse (Rush et al, 2006). Present strategies available to treat patients who 
do not respond to first-line antidepressant monotherapy include switching of 
antidepressant (either within or between classes); combination therapy in which multiple 
antidepressants are used simultaneously; augmentation of ongoing antidepressant 
monotherapy with adjunctive use of drugs such as mood stabilizers or atypical 
antipsychotics (Boland and Keller, 2006), and nonpharmacologic treatments including 
psychotherapy and phototherapy, vagus nerve stimulation, transcranial magnetic 
stimulation, and electroconvulsive therapy. Clearly, there remains a critically important 
unmet medical need for this patient population.
Existing antidepressants have a number of limitations, leading to considerable unmet 
medical need in the effective treatment of MDD, with up to 50% of patients with MDD 
having an inadequate response or failing current antidepressant therapy (ADT). Currently 
available first-line antidepressants (SSRIs, SNRIs) typically take 3 to 4 weeks or more of 
continuous daily dosing to relieve symptoms of MDD and are associated with side effects 
related to their pharmacological mechanisms of action (sexual dysfunction, weight gain, 
jitteriness, sleep disturbances), which are further associated with poor patient compliance 
(Masand, 2003; Ashton et al, 2005). Patients often experience undesirable side effects 
before they experience an improvement in depressive symptoms, which could lead to 
premature discontinuation of therapy. Taken together, these factors define significant 
areas for improvement of ADT. 


Naurex, Inc.
24
RAP-MD-33 Protocol Final
02 May 2018
Patients vary greatly in their response to antidepressants and it is not possible to reliably 
predict whether an individual patient will respond to a given antidepressant. This leads to 
clinicians often using a trial-and-error approach to identify an effective antidepressant. 
Due to the gradual development of the full therapeutic effect of currently available 
antidepressants, each antidepressant needs to be administered for 4 weeks or longer in 
order to determine the individual therapeutic benefit, making the process of finding an 
effective antidepressant lengthy for patients who are often severely depressed and at a 
high risk for suicide. A drug that could induce a rapid antidepressant effect would 
represent a major advancement for these patients.
Clearly, there is a substantial need for the development of novel treatments with a better 
safety/tolerability profile and a faster onset of full therapeutic benefit. Rapastinel has 
initially shown substantially improved safety/tolerability as well as promising efficacy, in 
both speed of onset and overall magnitude, for therapy in MDD. 
Rapastinel as a Novel Approach to Major Depressive Disorder Treatment
The mechanism of action of rapastinel is entirely different from that of first-line 
antidepressants (SSRIs, SNRIs) or adjuvant drugs currently approved for treatment of 
MDD such as atypical antipsychotics. Rapastinel is an N-methyl-D-aspartate receptor 
(NMDAR) modulator with a novel and complex pharmacological mechanism of action, 
acting as a nonselective agent at NR2 subunits and displaying properties as a functional 
partial agonist in a number of pharmacological assays. 
Rapastinel has demonstrated antidepressant properties in relevant animal models, 
displays cognitive enhancing properties in treated animals, and facilitates hippocampal 
long-term potentiation of synaptic transmission in preclinical models. In contrast to 
ketamine, no signal of abuse liability was detected in informative animal models. 
Rapastinel is available as an intravenous (IV) formulation only. In 2 Phase 2 clinical 
studies in patients with MDD, single IV doses of rapastinel 5 mg/kg and 10 mg/kg have 
been shown to produce marked antidepressant effects within 1 day that lasted for 
approximately 1 week or longer in responding patients. These antidepressant effects are 
very similar to ketamine’s effects when administered at a low dose as an infusion. In a 
systematic review and meta-analysis of ketamine and other NMDAR antagonists in the 
treatment of major depression, a single infusion of ketamine produced a rapid, yet 
transient antidepressant effect, accompanied by brief psychotomimetic and dissociative 
effects (Newport et al, 2015). 
The available Phase 1 and 2 data demonstrated a favorable safety and tolerability profile 
of rapastinel. In contrast to ketamine, rapastinel has not shown a high likelihood to induce 
psychotomimetic or dissociative effects in humans so far. 


Naurex, Inc.
25
RAP-MD-33 Protocol Final
02 May 2018
The purpose of this study is to assess the efficacy, safety, and tolerability of rapastinel 
relative to placebo in the prevention of relapse in patients with MDD.  The study is 
intended to support an application for regulatory approval of rapastinel as monotherapy 
treatment for MDD.


Naurex, Inc.
26
RAP-MD-33 Protocol Final
02 May 2018
8.0
STUDY OBJECTIVES
The objectives of this study are to evaluate the efficacy, safety, and tolerability of 
rapastinel relative to placebo in the prevention of relapse in patients with MDD.

Primary objective: To evaluate the efficacy of rapastinel (225 or 450 mg, IV, weekly 
or clinically driven schedule) versus placebo in the maintenance treatment of MDD,
as measured by time to relapse during the 52 weeks of the double-blind treatment 
period (DBTP)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
27
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 


Naurex, Inc.
28
RAP-MD-33 Protocol Final
02 May 2018
9.0
INVESTIGATIONAL PLAN
9.1
OVERALL STUDY DESIGN AND PLAN: DESCRIPTION
Study RAP-MD-33 is a multicenter, randomized-withdrawal, parallel-group, placebo-
controlled, maintenance study of rapastinel as monotherapy in adult patients with MDD 
who completed the RAP-MD-30, RAP-MD-31, or RAP-MD-32 DBTP.  The final visit 
from the lead-in study (ie, Visit 9) will serve as Visit 1 in Study RAP-MD-33. 
This study will be conducted in the following periods:

An 8- to 16-week, Open-label Treatment Period (OLTP) 

A 52-week, DBTP, randomized-withdrawal period during which stable responders 
from the open-label period will be randomized (1:1:1) to 1 of 3 double-blind 
treatment arms: 
o
Rapastinel weekly (IV, 450 mg or 225 mg)
o
Rapastinel clinically driven schedule (IV, 450 mg or 225 mg, variable 
interval, placebo on intervening weeks)
o
Placebo weekly (IV) 

A 2-week Safety Follow-up Period
Approximately 1400 patients are planned for enrollment in the OLTP to achieve 
approximately 600 randomized patients in the DBTP. When approximately 600 patients 
are randomized into the DBTP, enrollment in the OLTP will be closed.
A schematic of the study design is presented in Figure 9.1.3–1.  The Schedule of 
Evaluations is provided in Section 2.0.
9.1.1
Open-label Treatment Period
Patients will enroll from Study RAP-MD-30, RAP-MD-31, or RAP-MD-32, and the final 
visit from that study (Visit 9/ET [Week 6]) will serve as Visit 1 in Study RAP-MD-33. 
Patients will be screened at Visit 1 and those who meet entry criteria will also enter the 
OLTP at Visit 1 and will receive the first dose of open-label treatment (rapastinel) at 
Visit 1 to ensure continuity of treatment.


Naurex, Inc.
29
RAP-MD-33 Protocol Final
02 May 2018
The OLTP consists of weekly visits for at least 8 weeks (and up to 16 weeks). During this 
period, patients will be treated with weekly IV injections of rapastinel (450 mg or 225 
mg). The dose assigned in the OLTP will be blinded and be based on the dose received in 
the lead-in study such that those who received placebo, vortioxetine, or 450 mg or 900
mg rapastinel in the lead-in study will be assigned 450 mg rapastinel, while those who 
received 225 mg rapastinel in the lead-in study will be assigned 225 mg rapastinel.
The purpose of this period is to identify stable responders who will be eligible for the 
randomized-withdrawal period.
Patients will be monitored through the OLTP stability assessment.  A patient will be 
considered to have met OLTP stability criteria upon achieving both:

MADRS total score ≤ 12 with no more than 1 modest MADRS excursion 
(MADRS > 12 but ≤ 16) during 6 consecutive weeks, and  

MADRS total score ≤ 12 for 2 consecutive visits prior to randomization
Patients may meet OLTP stability assessment criteria at any point from Study Week 8 to 
Study Week 16.  
Patients who do not meet stability criteria within these timeframes will undergo the End-
of-Treatment/Early Termination assessments (Visit 69/Week 52/ET) at their last OLTP 
visit.  
Patients who discontinue from Study RAP-MD-33 OLTP will enter a 2-week safety 
follow-up period.
9.1.2
Double-Blind Treatment Period
Approximately 600 patients are planned for randomization in the DBTP. 
Upon meeting stability criteria, patients will enter the DBTP. Each patient entering the 
DBTP will be randomized 1:1:1 to 1 of 3 double-blind treatment arms:

Rapastinel weekly arm: weekly IV administration of rapastinel (450 mg or 225
mg, based on dose patient received in OLTP) 

Rapastinel clinically driven schedule arm: IV administration of rapastinel (450
mg or 225 mg, based on dose patient received in OLTP) given on a response-
based variable schedule depending on the clinical assessment at the respective 
visit with placebo given at intervening visits. 

Placebo weekly arm: weekly IV administration of placebo
At each visit during the DBTP, each patient will be assessed clinically to determine 
whether a patient is considered:


Naurex, Inc.
30
RAP-MD-33 Protocol Final
02 May 2018

“Clinically stable”, defined as meeting all of the below:
o
MADRS total score ≤ 12
o
≤ 4-point increase in MADRS total score from prior visit
o
≤ 1-point increase in CGI-S score from prior visit
o
Patient does not require intervention based on the discretion of the 
investigator
or 

“Clinically unstable”, defined as not meeting one or more of the criteria above
Implementation of the rapastinel clinically driven schedule arm will be based on 
individual patient response and clinical presentation. The study center investigator will 
submit the clinical assessment to the interactive web response system (IWRS) at each 
visit. Depending on the assigned treatment arm, the IWRS will dispense the following 
treatments in a blinded manner:

Rapastinel weekly arm: rapastinel (450 mg or 225 mg, based on dose patient 
received in OLTP), regardless of clinical assessment

Rapastinel clinically-driven schedule arm: 
o
“Clinically unstable”: rapastinel (450 mg or 225 mg, based on dose patient 
received in OLTP)
o
“Clinically stable”: placebo IV

Placebo weekly arm: placebo IV at each visit, regardless of clinical assessment
Patients will be monitored for relapse events defined as meeting any of the following 
criteria:

MADRS total score ≥ 18 at 2 consecutive MADRS assessments

≥ 2 increase in CGI-S score compared with that obtained at randomization

Risk of suicide as determined by the investigator

Need for hospitalization due to worsening of depression as determined by the 
investigator

Need for alternative treatment of depressive symptoms as determined by the 
investigator 
Upon meeting any of the relapse criteria at any visit in the DBTP, the patient will be 
considered a completer and the Visit 69/ET Visit procedures should be conducted. 


Naurex, Inc.
31
RAP-MD-33 Protocol Final
02 May 2018
Each randomized patient will be treated until relapse criteria are met, or until he/she has 
completed 52 weeks of double-blind treatment or discontinued for other reasons.  The 
study will be terminated when all randomized patients have either met relapse criteria, 
early terminated for other reasons, or completed 52 weeks of the DBTP and completed 
the safety-follow up period where appropriate.
Upon completion of the DBTP, patients will enter a 2-week safety follow-up period.
9.1.3
Safety Follow-up Period
All patients who complete or discontinue from the study should enter the 2-week safety 
follow-up period.
Additional follow-up visits may be scheduled within 30 days, if necessary, for safety 
reasons.
A schematic of the study design is presented in Figure 9.1.3–1. The Schedule of 
Evaluations is provided in Section 2.0 and detailed descriptions of each study visit can be 
found in Section 9.5.5.


Naurex, Inc.
32
RAP-MD-33 Protocol Final
02 May 2018
9.2
DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE 
OF CONTROL GROUPS
This multicenter, randomized-withdrawal, placebo-controlled, parallel-group,
maintenance study, was designed based on prior studies that established rapastinel 
efficacy and safety in adult patients with MDD. The placebo-controlled withdrawal 
design is considered standard to demonstrate effectiveness of long-term maintenance 
treatment (Borges et al, 2014; EMA/CHMP/185423/2010 Rev 2).
Study centers will have experience with the study population and will be encouraged to 
apply available guidelines to minimize patient risk or distress. 
Dose selection information is presented in Section 9.4.5. The planned dosing regimen is 
based on experience from previous rapastinel studies. 


Naurex, Inc.
33
RAP-MD-33 Protocol Final
02 May 2018
The 8- to 16-week OLTP was designed to ensure sustained response following continued 
rapastinel treatment. The double-blind design is included to minimize systematic bias 
resulting from the scale raters, patient, or investigator knowing the treatment being 
administered. Randomization at the beginning of the DBTP is expected to minimize 
patient selection bias and increase baseline comparability of the 3 treatment groups. 
The use of placebo control is critical to the study design both to understand the safety 
findings of the drug and to ensure that efficacy results can be interpreted. In this study, 
the placebo control is used during the DBTP to demonstrate the reemergence of MDD
symptoms upon withdrawal of rapastinel compared with patients who continue rapastinel 
treatment. Patients who continue rapastinel treatment should maintain improvement in 
their MDD symptoms, whereas those who switch to placebo should have a return of 
MDD symptoms. 
The duration of the DBTP of 52 weeks was selected to provide sufficient time to 
demonstrate MDD relapse upon withdrawal of rapastinel and this duration is at the upper 
end of what is typically employed in withdrawal design maintenance studies 
(Borges et al, 2014). 
The 2-week safety follow-up period allows continued patient monitoring after the IP has 
been discontinued.
In Study RAP-MD-33, safety and efficacy assessments are included at appropriate 
intervals to determine efficacy, safety, and tolerability. In the event of insufficient 
therapeutic response or worsening of the patient’s initial condition, the IP may be 
discontinued at the investigator’s discretion and an alternative treatment will then be 
allowed (Section 9.4.12). 
An independent Data and Safety Monitoring Board (DSMB) will evaluate safety data 
during the study (Section 9.8).


Naurex, Inc.
34
RAP-MD-33 Protocol Final
02 May 2018
9.3
SELECTION OF STUDY POPULATION
9.3.1
Inclusion Criteria
Note: Patients roll over into RAP-MD-33 after completion of the lead-in study (RAP-
MD-30, RAP-MD-31, or RAP-MD-32); therefore medical, psychiatric, and medication 
histories from Visit 1 of the lead-in study will be used to support entry into Study RAP-
MD-33.
To be eligible to participate in the study, patients must meet the following criteria:
Criteria to be assessed at Visit 1
1. Written informed consent, obtained from the patient before the initiation of any 
study-specific procedures (Section 5.3) 
2. Completion of Study RAP-MD-30, RAP-MD-31, or RAP-MD-32
3. Male or female outpatients, 18 to 75 years of age (at time of entry to lead-in study)
 
 
 
 
 
5. If female of childbearing potential, has a negative serum β-human chorionic 
gonadotropin (β-hCG) pregnancy test.  Because Visit 1 pregnancy test results will not 
be available on the day of Visit 1, patients can be discontinued at Visit 2 if Visit 1 
pregnancy test is positive.
6.


Naurex, Inc.
35
RAP-MD-33 Protocol Final
02 May 2018
9.3.2
Exclusion Criteria
Note: Patients roll over into Study RAP-MD-33 after completion of the lead-in study 
(RAP-MD-30, RAP-MD-31, or RAP-MD-32); therefore medical, psychiatric, and 
medication histories from Visit 1 of the lead-in study will be used to support entry into
Study RAP-MD-33.
Patients who meet any of the following criteria will not be eligible to participate in the 
study:
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
36
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
9.3.3
Removal of Patients from Therapy or Assessment
A premature discontinuation will occur when a patient who signed the ICF ceases 
participation in the study, regardless of circumstances, before the completion of the study 
visits and procedures. Patients can be prematurely discontinued from the study after 
careful consideration for one of the following reasons:

Screen failure (failure to meet inclusion/exclusion criteria)

Pregnancy

Withdrawal of consent 

AE

Lack of efficacy

Protocol violation

Noncompliance with IP


Naurex, Inc.
37
RAP-MD-33 Protocol Final
02 May 2018

Lost to follow-up 

Study terminated by sponsor

Study center terminated by sponsor

Other 
All treated patients who prematurely discontinue from the study, regardless of cause, 
should be seen for a final assessment at an ET Visit. A final assessment will be defined as 
completion of the evaluations scheduled for all patients at Visit 69. All treated patients 
discontinuing the study prematurely should enter the 2-week safety follow-up period.
Patients who discontinue from the study and do not return to the study center for final 
assessments must be requested in writing to return to the study center for a final 
assessment. A copy of the letter, together with the source documentation, will be kept in 
the investigator’s files. The reason for premature discontinuation from the study will be 
recorded on the Study Termination Page of the eCRF. Study center staff will be contacted 
by the sponsor (or designee) after each premature discontinuation to ensure proper 
characterization of the reason for discontinuation is captured.
9.3.3.1
Criteria for Required Removal of Patients from Therapy or 
Assessment
Any patient who meets any of the following criteria at any point during the study must be 
withdrawn from participation, due to AEs related to suicide:

A suicide attempt

Significant risk, as judged by the investigator, based on the psychiatric 
interview or information collected in the C-SSRS

MADRS Item 10 score ≥ 5
In the event that a patient is withdrawn for a suicide-related AE, the patient should be 
referred for additional treatment or hospitalization, as clinically indicated, in addition to 
withdrawing the patient from the study.
9.3.4
Patient Replacement Procedures
Patients in this study who prematurely discontinue treatment will not be replaced.


Naurex, Inc.
38
RAP-MD-33 Protocol Final
02 May 2018
9.4
TREATMENTS
During the OLTP, all eligible patients will receive open-label, once-weekly IV rapastinel 
(225 mg or 450 mg). Patients who meet eligibility criteria at the end of the OLTP will be 
randomized in a double-blind fashion to 1 of 3 treatment groups: rapastinel weekly, 
rapastinel on a clinically driven schedule, or placebo weekly.
9.4.1
Treatments Administered
IP will only be administered to eligible patients by a medically qualified person as per the 
local and/or state regulations. The range of persons who can administer an IV can be a 
physician, a physician assistant, nurse, or nurse practitioner, etc, depending on the local 
and/or state law.  
IP should be administered after all efficacy and safety assessments with the exception of 
assessments specified in this protocol as requiring postdose administration.
The IP will be administered using the provided prefilled syringes in a “slow bolus” 
injection to an upper extremity vein within approximately 1 to 2 minutes to each study 
patient. 
During IP administration and until completion of postadministration assessments, a 
licensed physician must be immediately available and in close proximity to the patient(s) 
to attend to medical emergencies.  The facility must have the capabilities, in accordance 
with the country and/or local regulations/standard of care, to resuscitate a patient in the 
event of a medical emergency.  
At IP administration visits, the patient should not be released from the study center until 
the following are completed:

Postadministration pulse rate and BP measures (approximately 15 minutes after 
administration)

Patient is clinically assessed and determined to not be at increased risk of 
suicidality in the opinion of the investigator (or medically qualified 
subinvestigator)

Patient is assessed for mental status and is determined to be free of perceptual 
disturbances or other conditions that would deem them not ready for release from 
the study center, in the opinion of the investigator (or medically qualified 
subinvestigator)


Naurex, Inc.
39
RAP-MD-33 Protocol Final
02 May 2018

A physician licensed in the country, state, or other local regulatory authority 
(investigator or subinvestigator) determines that they are medically able to leave 
the study center and provides written signoff not less than 15 minutes following 
administration (see IV Administration and Evaluation Notes document in Study
Reference Manual)
9.4.2
Identity of Investigational Products
Rapastinel 450-mg IV Prefilled Syringes: 
 
 
Rapastinel 225-mg IV Prefilled Syringes: 
 
 
Placebo rapastinel IV Prefilled Syringes: 
 
 
 
 
 
The prefilled syringe will be labeled with the protocol number and kit number. The study 
center personnel will write the PID number on the prefilled syringe associated with the 
kit mentioned above. The prefilled syringe label will not have a tear-off portion and will 
remain on the prefilled syringe.


Naurex, Inc.
40
RAP-MD-33 Protocol Final
02 May 2018
9.4.3
Handling of Investigational Products
The IP must be stored in a secure area and administered only to patients entered into the 
clinical study, at no cost to the patient, in accordance with the conditions specified in this 
protocol.
 
Study centers must report any temperature 
excursions as described in the Study Reference Manual or contact the sponsor or its 
designee for further instructions. 
At the end of the study, all IP must be accounted for. In addition, at the end of the study, 
all unused IP and empty IP packages should be returned to the sponsor or the local 
distributor at the address provided in the Study Reference Manual.
9.4.4
Method of Assigning Patients to Treatment Groups
After a patient signs the consent form at Visit 1, study personnel will register the patient 
in the IWRS.  All patients entering from the lead-in studies (RAP-MD-30, RAP-MD-31, 
or RAP-MD-32) will be identified using the same PID that was assigned by the IWRS in 
the lead-in study. 
This PID number will be used to identify the patient throughout the study (ie, at all 
periods of the study).
The IP will be labeled with medication kit numbers. The IWRS will provide the study 
center with the specific medication kit number(s) for each patient at each administration. 
Study centers will dispense IP according to the IWRS instructions. Study centers will also 
log on to the IWRS at subsequent visits to obtain an IP kit number for dispensing the IP. 
Study centers will receive the IWRS confirmation notifications for each transaction. All 
notifications are to be maintained with the study source documents.
9.4.5
Selection of Dosages in the Study
The doses of rapastinel in this study were selected based on 2 Phase 2 clinical studies in 
patients with MDD, in which single IV doses of rapastinel 5 mg/kg and 10 mg/kg were
shown to produce marked antidepressant effects within 1 day that lasted approximately
1 week or longer in responding patients.
A 450-mg IV unit dose is expected to be appropriate for most patients as this represents a 
dose of 4.5 mg/kg in a 100-kg patient and a dose of 9 mg/kg in a 50-kg patient.


Naurex, Inc.
41
RAP-MD-33 Protocol Final
02 May 2018
A 225-mg IV unit dose (equivalent to 2.25 mg/kg in a 100-kg patient and a dose of 4.5
mg/kg in a 50-kg patient) is available only to patients entering from RAP-MD-30 to 
allow for further evaluation of the dose-response profile after multiple dosing.
9.4.6
Selection and Timing of Dose for Each Patient
9.4.6.1
Open-label Treatment Period
During the OLTP, patients will be treated with weekly IV injections of rapastinel (450 
mg or 225 mg). The dose assigned in the OLTP will be blinded and be based on the dose 
received in the lead-in study such that those who received placebo, vortioxetine, 450 mg 
or 900 mg rapastinel in the lead-in study will be assigned 450 mg rapastinel, while those 
who received 225 mg rapastinel in the lead-in study will be assigned 225 mg rapastinel.
9.4.6.2
Double-blind Treatment Period
During the DBTP, patients will be randomized 1:1:1 to 1 of 3 double-blind treatment 
arms:

Rapastinel weekly arm: weekly IV administration of rapastinel (450 mg or 225
mg, based on dose patient received in OLTP) 

Rapastinel clinically driven schedule arm: IV administration of rapastinel (450
mg or 225 mg, based on dose patient received in OLTP) given on a response-
based variable-schedule depending on the clinical assessment at the respective 
visit with placebo given at intervening visits. 

Placebo weekly arm: weekly IV administration of placebo
At each visit during the DBTP, each patient will be assessed clinically to determine 
whether a patient is considered:

“Clinically stable”, defined as meeting all of the below:
o
MADRS total score ≤ 12
o
≤ 4-point increase in MADRS total score from prior visit
o
≤ 1-point increase in CGI-S score from prior visit
o
Patient does not require intervention based on the discretion of the 
investigator
or 

“Clinically unstable”, defined as not meeting one or more of the criteria above
Implementation of the rapastinel clinically driven schedule arm will be based on 
individual patient response and clinical presentation. The study center investigator will
submit the clinical assessment to the IWRS at each visit. Depending on the assigned 
treatment arm, the IWRS will dispense the following treatments in a blinded manner:


Naurex, Inc.
42
RAP-MD-33 Protocol Final
02 May 2018

Rapastinel weekly arm: rapastinel (450 mg or 225 mg, based on dose patient 
received in OLTP), regardless of clinical assessment

Rapastinel clinically-driven schedule arm: 
o
“Clinically unstable”: rapastinel (450mg or 225 mg, based on dose patient 
received in OLTP)
o
“Clinically stable”: placebo IV

Placebo weekly arm: placebo IV at each visit, regardless of clinical assessment
9.4.6.3
Safety Follow-up Period 
No IP is administered during the safety follow-up period.
9.4.7
Blinding
For the OLTP, the list of patient randomization codes from the lead-in studies will be 
implemented by the IWRS vendor (an electronic version will be stored on a secure 
server). This list will identify each patient by randomization number and include the 
patient’s corresponding treatment assignment from the lead-in study to establish 
appropriate dosing of rapastinel in the OLTP.
For the DBTP, a list of patient randomization codes will be generated by Statistical 
Programming and implemented by the IWRS vendor (an electronic version will be stored 
on a secure server). This list will identify each patient by randomization number and 
include the patient’s corresponding treatment assignment in the DBTP.
All study treatments will be provided in identical syringes and cartons to maintain 
masking of the study.
9.4.8
Unblinding
Any unblinding at the study center level should be done only in an emergency that 
requires the IP to be identified for the medical management of the patient. The 
investigator must notify the Study Physician immediately (refer to Appendix II) and a full 
written explanation must be provided if the blind is broken. Before the IP is unblinded, 
every attempt should be made to discuss the case with the Study Physician. Breaking the 
code at the study center will immediately disqualify the patient from further participation 
in the study.
Treatment codes may be broken by Global Drug Safety for regulatory reporting purposes. 
In such cases, the study staff will be kept blinded and the patient will not need to be 
disqualified from the study.
In an emergency, the investigator can obtain the treatment assignment of any patient at 
his or her study center through the IWRS. 


Naurex, Inc.
43
RAP-MD-33 Protocol Final
02 May 2018
9.4.9
Prior and Concomitant Therapy
A list of example medications that are allowed and not allowed as concomitant 
medications for either episodic or chronic use is provided in Appendix III. 
Medication history (psychotropic medication history during the previous 5 years [to the 
extent possible] and all other medications during the past 12 months) will be recorded at 
Visit 1 of the lead-in study in the eCRF. Thereafter, any changes in concomitant 
medications or any new medications added will be recorded in the eCRF.
9.4.9.1
Permitted Medications/Treatments
 
 
 
 
 
 
 
 
 


Naurex, Inc.
44
RAP-MD-33 Protocol Final
02 May 2018
For Anxiety or Agitation
 
 
9
2
 
 
 
 
 
.
9.4.10
Other Restrictions
9.4.10.1
Alcohol 
It is recommended that patients abstain from alcohol consumption during the study.
9.4.10.2
Contraception
For purposes of this study, females will be considered of childbearing potential unless 
they are naturally postmenopausal or permanently sterilized (ie, hysterectomy). Natural 
menopause is defined as the permanent cessation of menstrual periods, determined
retrospectively after a woman has experienced 12 months of amenorrhea without any 
other obvious pathological or physiological cause. 


Naurex, Inc.
45
RAP-MD-33 Protocol Final
02 May 2018
For women of childbearing potential and male partners of women of childbearing 
potential who may participate in the study, the following methods of contraception, if 
properly used, are generally considered reliable: hormonal contraceptives (ie, oral, patch, 
injection, implant), male condom with intravaginal spermicide, diaphragm or cervical cap 
with spermicide, vaginal contraceptive ring, intrauterine device [IUD], surgical 
sterilization (bilateral tubal ligation, bilateral salpingectomy), implantable permanent 
birth control device (ie Essure; note: device must be in place at least 3 months and 
completed confirmation test), vasectomized partner, or complete abstinence for the 
duration of the study (periodic abstinence [such as calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Note: In Germany, the Czech Republic, and other local regions as applicable, acceptable 
methods of contraception include complete abstinence; single barrier (diaphragm or 
condom) combined with the use of IUD or contraceptive (oral, implantable, or 
injectable); or double barrier (diaphragm with condom).
The investigator and each patient will determine the appropriate method of contraception 
for the patient during the participation in the study with consideration for local regulatory 
or IRB/EC requirements.
See Section 9.5.2.3 for pregnancy reporting procedures.
9.4.11
Monitoring Treatment Compliance
IP compliance during any period will be closely monitored by capturing the date and time 
of each injection of IP. If a scheduled IV injection does not occur, the sponsor must be 
notified and the reason recorded.
9.4.12
Treatment After Discontinuation
Patients whose MDD symptoms worsen or are determined by the investigator not to be 
adequately controlled prior to completing the OLTP or DBTP will be allowed to 
discontinue the study and start appropriate treatment at the investigator’s discretion. This 
new treatment will not be provided by the sponsor. Patients who initiate a new treatment 
for MDD must be discontinued from the study.


Naurex, Inc.
46
RAP-MD-33 Protocol Final
02 May 2018
9.5
EFFICACY AND SAFETY ASSESSMENTS
9.5.1
Diagnostic and Efficacy Assessments
 
9.5.1.2
Efficacy Assessments
The efficacy assessments will be administered by a psychiatrist, doctoral-level clinical 
psychologist, or other clinician who has extensive professional training and experience in 
the diagnosis of mental illness and who meets the training requirements and 
qualifications standards set by the sponsor and rater training vendor.
 
 
 
 
 
 
 
 
 
  
 
 
 
 


Naurex, Inc.
47
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
  
 
 
 
9.5.2
Safety Assessments
Patients must be evaluated by a physician or an appropriately trained health care 
professional at every visit and the evaluation must be documented. The procedures 
discussed below will be completed at the designated visits.
9.5.2.1
Adverse Events
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH-E2A).
For the purpose of the study center’s data collection responsibilities, any untoward event 
that was reported from the time the patient signed the ICF until 30 days after the final 
protocol-defined study visit or the last known dose of IP (if the final visit does not occur)
is to be considered an AE.


Naurex, Inc.
48
RAP-MD-33 Protocol Final
02 May 2018
Examples of AEs are as follows:

Changes in the general condition of the patient

Subjective symptoms offered by or elicited from the patient

Objective signs observed by the investigator or other study center personnel

All diseases that occur after signing informed consent, including any change in 
severity or frequency of pre-existing disease

All clinically relevant abnormalities in laboratory values or clinically relevant 
physical findings that occur during the study schedule
Please note that medical procedures scheduled prior to consenting, but occurring during 
the study should not be captured as AEs, but should be listed in the medical history if 
related to a pre-existing condition.
9.5.2.1.1
Causality Assessment
For each AE, the investigator must provide an assessment of causal relationship to the IP. 
The causality assessment must be recorded on the appropriate AE reporting page of the 
patient’s eCRF. Causal relationship must be assessed by answering the following 
question:
Is there a reasonable possibility the IP caused the event?
Yes:
There is evidence to suggest a causal relationship between the IP and AE, ie: 

There is a reasonable temporal relationship between the IP and the event, 
and/or 

The event is unlikely to be attributed to underlying/concurrent disease or other 
factors, and/or

Positive dechallenge and/or rechallenge exist
No:
There is no evidence to suggest a causal relationship between the IP and AE, 
ie:

There is no reasonable temporal relationship between the IP and the event, or

The patient did not take the IP, or


Naurex, Inc.
49
RAP-MD-33 Protocol Final
02 May 2018

The event is likely to be attributed to underlying/concurrent disease or other 
factors, or

The event is commonly occurring in the (study) population independent of IP
exposure
9.5.2.1.2
Severity Assessment
The investigator will provide an assessment of the severity of each AE by recording a 
severity rating on the appropriate AE reporting page of the patient’s eCRF. Severity,
which is a description of the intensity of manifestation of the AE, is distinct from 
seriousness, which implies a patient outcome or AE-required treatment measure 
associated with a threat to life or functionality (Section 9.5.2.1.3). Severity will be 
assessed according to the following scale:
Mild:
A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living.
Moderate:
A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort, but poses no significant or permanent risk of harm to 
the research participant.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention.
9.5.2.1.3
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:

Results in death

Is life threatening

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity, or

Is a congenital anomaly/birth defect


Naurex, Inc.
50
RAP-MD-33 Protocol Final
02 May 2018
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based on appropriate medical judgment, 
they may jeopardize the patient and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in patient hospitalization, or the 
development of IP dependency or drug abuse.
Emergency room visits that do not result in hospitalization should be evaluated for one of 
the other serious outcomes to determine whether they qualify as SAEs.
Preplanned hospitalizations (eg, elective procedures for pre-existing conditions that did 
not worsen, such as cosmetic surgery and hysterectomy) are excluded from SAE 
reporting.
9.5.2.1.4
Reporting Adverse Events and Serious Adverse Events
At each visit, patients are to be queried regarding any AEs or SAEs that have occurred 
since the previous visit. Patients will be asked to volunteer information with a nonleading 
question such as, “How do you feel since your last visit?” Study center personnel will 
record all pertinent information in the patient’s eCRF. 
All AEs must be recorded on the appropriate AE reporting page of the patient’s eCRF 
whether or not they are considered causally related to the IP.
For every AE, the investigator must:

Provide an assessment of the seriousness of the event (ie, is it an SAE?), as well as 
the severity and casual relationship

Document all actions taken with regard to the IP

Detail any other treatment measures taken for the AE

Document the outcome of the AE
In addition, patients are to be reminded, as described in the ICF and in accordance with 
Section 9.5.2.1, to notify study center personnel of any AEs occurring during the 30-day 
poststudy period. Any AEs reported by the patient (or patient representative) during this 
period are to be recorded in original source documents. AEs are also to be recorded in the 
eCRF if at least one of the following conditions is met: 1) the event meets the criteria for 
an SAE (see Sections 9.5.2.1.3 and 9.5.2.1.4), and/or 2) the event is judged by the 
investigator to be potentially causally related to IP (Section 9.5.2.1.1).


Naurex, Inc.
51
RAP-MD-33 Protocol Final
02 May 2018
Any AEs that are ongoing at the time of the final protocol-defined study visit will be 
followed until the condition returns to prestudy status, has resolved or stabilized, or can 
be explained as being unrelated to the IP. If a follow-up visit is deemed necessary for 
appropriate safety surveillance, it will take place within 30 days of the final 
protocol-defined study visit.
9.5.2.2
Immediate Reporting of Serious Adverse Events
The sponsor is required to inform worldwide regulatory authorities of SAEs that meet 
specific criteria. Therefore, the sponsor must be notified immediately regarding any SAE 
that occurs after informed consent is obtained.
Within 24 hours of learning of any AE that meets one of the criteria for an SAE, the 
study center personnel must report the event to Global Drug Safety on the SAE Form for 
Clinical Trials. The Study Physician may also be notified by telephone.
If, during follow-up, any nonserious AE worsens and eventually meets the criteria for an 
SAE, that AE should be recorded as a new SAE. 
The study center must transmit the SAE Form for Clinical Trials to the SAE email 
address or fax number shown below. Even if an initial report is made by telephone, the 
SAE Form for Clinical Trials completed with all available details must still be emailed or 
faxed within 24 hours of knowledge of the event at the study center.
Supplemental information should be submitted as soon as available and may include 
laboratory results, radiology reports, progress notes, hospital admission and emergency 
room notes, holding and observation notes, discharge summaries, autopsy reports, and 
death certificates.
The investigator is expected to take all therapeutic measures necessary for resolution of 
the SAE. Any medications or procedures necessary for treatment of the SAE must be 
recorded on the appropriate pages of the patient’s eCRF. All SAEs are to be followed by 
the study staff until resolution or until the SAE is deemed stable. The sponsor may 
contact the study center to solicit additional information or follow up on the event.


Naurex, Inc.
52
RAP-MD-33 Protocol Final
02 May 2018
9.5.2.3
Reporting of Pregnancies Occurring During the Study
Study center personnel must report every pregnancy from the time the patient signs the 
ICF until 30 days after the last dose of IP. Within 24 hours of learning of the pregnancy, 
the study center personnel must report the event to Global Drug Safety on the Clinical 
Trial Pregnancy Form and email or fax it to the SAE/Pregnancy email address or fax 
number provided in Section 9.5.2.2, even if no AE has occurred. Pregnancies in female 
partners of male patients occurring during the time frame described above must also be 
reported. 
Any pregnancy of a patient treated with IP must be followed to term and the outcome 
reported by completing a follow-up Clinical Trial Pregnancy Form. If the pregnancy is 
associated with an SAE (eg, if the mother is hospitalized for hemorrhage), a separate 
SAE Form for Clinical Trials must be filed as described in Section 9.5.2.2, with the 
appropriate serious criterion (eg, hospitalization) indicated in addition to the pregnancy 
form.
9
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
53
RAP-MD-33 Protocol Final
02 May 2018
9
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
54
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
55
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
9
6
 
 
 
 


Naurex, Inc.
56
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
9
7
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
57
RAP-MD-33 Protocol Final
02 May 2018
9
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
58
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 


Naurex, Inc.
59
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
60
RAP-MD-33 Protocol Final
02 May 2018
9
1
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
61
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
62
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
63
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
64
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
65
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 


Naurex, Inc.
66
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
67
RAP-MD-33 Protocol Final
02 May 2018

 
 
 
 
 
 


Naurex, Inc.
68
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
69
RAP-MD-33 Protocol Final
02 May 2018

 
9
2
 
 
 
 
 
 
 
 
 


Naurex, Inc.
70
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 


Naurex, Inc.
71
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 


Naurex, Inc.
72
RAP-MD-33 Protocol Final
02 May 2018

 
 
 
 
 
 
 


Naurex, Inc.
73
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 


Naurex, Inc.
74
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 


Naurex, Inc.
75
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 


Naurex, Inc.
76
RAP-MD-33 Protocol Final
02 May 2018

 
 
 
 
9
4
 
 
 
 
9.5.5.5
Unscheduled Visits
Unscheduled visits can be performed if safety concerns arise and at the discretion of the 
investigator. Additional examinations may be performed as necessary to ensure the safety 
and well-being of the patients during the study.


Naurex, Inc.
77
RAP-MD-33 Protocol Final
02 May 2018
9.6
DATA QUALITY ASSURANCE
9.6.1
Data Monitoring
Before any patient enters the study, a representative of the sponsor will meet with the 
investigator and the study center staff to review the procedures to be followed during the 
study. Electronic data capture (EDC) functionality training is provided via 
computer-based training to train investigators and authorized designees on recording the 
data in the eCRFs using the EDC system. After the first patient is enrolled, the sponsor
representative, a Regional Site Manager or designee, will periodically monitor the 
progress of the study by conducting on-site visits. This Regional Site Manager or 
designee will review query statuses remotely, possibly warranting more frequent 
communication and/or study center visits with the investigator and the study center staff. 
The investigator will make available to the Regional Site Manager or designee source 
documents (written notes and electronic medical records, if used), signed consent forms, 
and all other study-related documents. The investigator and the study center staff will be 
responsible for data entry of patient data into the eCRFs via the EDC system, resolving 
data queries generated via the EDC system and providing missing or corrected data. The 
investigator or designee will be responsible for approving all changes performed on the 
data, and endorsing the patient data within the EDC system. This approval method will 
include applying an electronic signature linked to a uniquely assigned username and 
password that together will represent a traditional handwritten signature used in the past.
9.6.2
Data Recording and Documentation
Data collection will involve the use of the EDC system, to which only authorized 
personnel will have access. Patient’s data are to be entered into the EDC system by the 
investigator or designee using their assigned EDC user account. After data entry into the 
EDC system by the investigator or designee, a combination of manual and programmatic 
edit checks will be used to review the data for completeness, logic, and adherence to 
study protocol. As a result of these edit checks, data monitoring, and reviews, queries 
may be electronically issued to the study center and should be answered electronically via 
the EDC system.
Each query will carry identifying information (assigned username, date, and time) to 
assist the sponsor and the investigator on the origin of the data clarification request and 
the response provided by the investigator. All data changes made to the patient’s data via 
a data query will be approved by the investigator prior to final database lock.
After all data have been reviewed and all issues have been resolved, the database will be 
locked.


Naurex, Inc.
78
RAP-MD-33 Protocol Final
02 May 2018
All data collected in the context of this study will be stored and evaluated per regulatory 
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated in such a way as to guarantee patient confidentiality in accordance with the 
legal stipulations applying to confidentiality of data. Study records (eg, copies of eCRFs, 
laboratory reports, regulatory documents) will be retained at the study center, along with 
adequate source documentation, according to FDA and ICH requirements. All study 
records must be available for inspection by the sponsor, its authorized representatives, the 
FDA, or other health authorities.
 
. Source documents 
will be used at the study centers and may include a patient’s medical record, hospital 
charts, clinic charts, the investigator’s patient study files, as well as the results of 
diagnostic tests such as laboratory tests, ECGs, etc. A centralized clinical laboratory will 
be used for the analysis of all blood samples. Additional information on the collection 
and handling of samples is detailed in the Lab Procedure Manual.
9.7
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
9.7.1
Analysis Populations
Four populations will be considered in the statistical analysis of the study, as specified in 
the following subsections.
9.7.1.1
Open-label Safety Population
The Open-label Safety Population will consist of all patients in the Screened Population 
who received at least 1 dose of open-label rapastinel during the OLTP of the study.
9.7.1.2
Open-label Modified Intent-to-Treat Population
The Open-label modified Intent-to-Treat (Open-label mITT) Population will consist of all 
patients in the Open-label Safety Population who had at least 1 postbaseline assessment 
of the MADRS during the OLTP of the study.
9.7.1.3
Double-Blind Safety Population
The Double-blind Safety Population will consist of all patients in the randomized patients
who received at least 1 dose of double-blind IP.


Naurex, Inc.
79
RAP-MD-33 Protocol Final
02 May 2018
9.7.1.4
Double-Blind Modified Intent-to-Treat Population
The Double-blind modified Intent-to-Treat (Double-blind mITT) Population will consist 
of all patients in the Double-blind Safety Population who had at least 1 
postrandomization assessment of the MADRS or the CGI-S during the DBTP of the 
study.
9.7.1.5
Pharmacokinetic Population
The PK Population will consist of all patients in the Safety Population with at least 1 
evaluable PK sample.
9.7.2
Patient Disposition
The number and percentage of patients who entered the OLTP, who prematurely 
discontinued from the OLTP, who completed the OLTP, who met or did not meet the 
criteria to enter the DBTP at the end of the OLTP, and who entered the DBTP will be 
summarized overall and by reasons for premature discontinuation for all enrolled patients 
in the OLTP. Similarly, the number and percentage of patients who completed the DBTP 
and who prematurely discontinued from the DBTP will be summarized overall, by 
double-blind treatment group, and by reasons for premature discontinuation for the all 
randomized patients in the DBTP.
9.7.3
Demographics and Other Baseline Characteristics
Demographic parameters and other baseline characteristics (eg, age, race, ethnicity, sex, 
weight, height, body mass index) will be summarized overall for the Open-label mITT
Populations and by treatment group for the Double-blind modified ITT population. 
9.7.4
Extent of Exposure and Treatment Compliance
9.7.4.1
Extent of Exposure
Exposure to open-label rapastinel for the Open-label Safety Population during the OLTP
will be summarized for treatment duration, calculated as the number of days from the 
date of the first dose of open-label rapastinel taken to the date of the last dose taken 
during the OLTP, inclusive. Descriptive statistics (number of patients, mean, SD, 
minimum, median, and maximum) will be presented.
Exposure to double-blind IP for the Double-blind Safety Population during the DBTP 
will be summarized for treatment duration, calculated as the number of days from the 
date of the first dose of double-blind IP taken to the date of the last dose taken during the 
DBTP, inclusive. Descriptive statistics (number of patients, mean, SD, minimum, 
median, and maximum) will be presented by treatment group.


Naurex, Inc.
80
RAP-MD-33 Protocol Final
02 May 2018
9.7.4.2
Prior and Concomitant Medication
Prior medication is defined as any medication started before the date of first dose of 
open-label IP. Concomitant medication during the OLTP is defined as any medication 
taken on or after the date of the first dose of open-label IP during the OLTP. Concomitant 
medication during the DBTP will be defined as any medication taken on or after the date 
of the first dose of double-blind IP.
The use of prior medication will be summarized by the number and percentage of patients 
receiving each medication within each therapeutic class for the Open-label Safety 
Population. The use of concomitant medications during the OLTP will be summarized by 
the number and percentage of patients receiving each medication within each therapeutic 
class for the Open-label Safety Population. The use of concomitant medications during 
the DBTP will be summarized by treatment group by the number and percentage of 
patients receiving each medication within each therapeutic class for the Double-blind 
Safety Population. Multiple use of the same medication by a patient will only be counted 
once.
9.7.4.3
Measurement of Treatment Compliance
Dosing compliance for a specified period will be defined as the total number of IV doses 
actually taken by a patient during that period divided by the number of IV doses that were 
expected to be taken during the same period multiplied by 100. The total number of IV 
doses actually taken during a specific time period is calculated as the sum of IV doses 
taken during that period as obtained from the study medication record. The number of IV 
doses expected to be taken for a specific treatment period will be the number of weeks in 
that period. 
Descriptive statistics for open-label IP compliance will be presented for the OLTP for the 
Open-label Safety Population. Descriptive statistics for double-blind IP compliance will 
be presented by treatment group for the DBTP for the Double-blind Safety Population.
9.7.5
Efficacy Analyses
All efficacy analyses for the OLTP will be performed using the Open-label mITT 
Population. All efficacy analyses for the DBTP will be performed using the Double-blind 
mITT Population. The baseline of the lead-in study will be used as the baseline for the
OLTP and the DBTP. All statistical tests will be 2-sided hypothesis tests performed at the 
5% level of significance and all confidence intervals (CIs) will be 2-sided 95% CIs, 
unless stated otherwise.
An additional analysis plan specific to European Medicines Agency will be presented in a 
stand-alone document.


Naurex, Inc.
81
RAP-MD-33 Protocol Final
02 May 2018
9.7.5.1
Primary Efficacy Analyses
The primary efficacy parameter is the time to first relapse during the 52 weeks of the 
DBTP, defined as the number of days from the randomization date of DBTP to the 
relapse date during the 52 weeks of the DBTP. Relapse during the DBTP is defined as 
meeting any of the following criteria:

MADRS total score ≥ 18 at 2 consecutive visits

≥ 2 increase in CGI-S score compared with that obtained at randomization

Risk of suicide as determined by the investigator

Need for hospitalization due to worsening of depression as determined by the 
investigator

Need for alternative treatment of depressive symptoms as determined by the 
investigator 
For patients who did not meet the above relapse criteria during the 52 weeks of the 
DBTP, the time to relapse will be censored at the time of completion or discontinuation 
from the study, or 52 weeks, whichever is earlier.
The primary efficacy analysis will compare the time to first relapse between placebo and 
rapastinel treatment groups in the respective time-frame (within the 52 weeks of the 
DBTP) using the log-rank test. The primary null hypothesis is that the distribution of the 
time to relapse for each of the rapastinel treatment groups is not different from that for 
the placebo treatment group. 
Estimates of the hazard ratio and 95% CI will be based on the Cox proportional hazards 
model with treatment group as an explanatory variable. The cumulative distribution 
function of time to relapse will be characterized by the Kaplan-Meier curves.
The Hochberg procedure will be used to control the overall type I error rate at the 0.05 
level for comparisons between each of rapastinel treatment groups and the placebo. 
 


Naurex, Inc.
82
RAP-MD-33 Protocol Final
02 May 2018

 
 
 
 
9.7.6.1
Adverse Events
AEs will be coded by system organ class (SOC) and preferred term using the Medical 
Dictionary for Regulatory Activities.
An AE (classified by preferred term) that occurs during the OLTP or thereafter will be 
considered a treatment-emergent adverse event (TEAE) if it was not present before the 
date of the first dose of IP in the OLTP or was present before the first dose of IP in the 
OLTP and increased in severity during the OLTP or thereafter. If more than 1 AE is 
reported before the date of the first dose of IP in the OLTP and coded to the same 
preferred term, the AE with the greatest severity will be used as the benchmark for 
comparison with the AEs occurring during the OLTP that were also coded to that 
preferred term.
An AE (classified by preferred term) that occurs during the DBTP of the study will be 
considered a newly emergent adverse event (NEAE) if the AE was not present before the 
first dose of the double-blind IP or it was present before the first dose of the double-blind 
IP and increased in severity during the DBTP. If more than 1 AE is reported before the 
first dose of the double-blind IP and coded to the same preferred term, the AE with the 
greatest severity will be used as the benchmark for comparison with the AEs occurring 
during the DBTP that were also coded to that preferred term. An AE that occurs more 
than 30 days after the date of the last dose of IP will not be counted as a NEAE.


Naurex, Inc.
83
RAP-MD-33 Protocol Final
02 May 2018
The number and percentage of patients reporting TEAEs during the OLTP will be 
tabulated by SOC and preferred term. Similarly, the number and percentage of patients 
reporting NEAEs during the DBTP will be tabulated by SOC and preferred term. The 
number and percentage of patients in each treatment group reporting TEAEs and NEAEs 
during the DBTP will be tabulated by SOC and preferred term; by SOC, preferred term, 
and severity; and by SOC, preferred term, and causal relationship to the IP. If more than 
1 AE is coded to the same preferred term for the same patient during the same treatment 
period, the patient will be counted only once for that preferred term using the most severe 
and most related occurrence for the summarization by severity and by causal relationship 
to the IP.
The distribution of TEAEs and NEAEs by severity and relationship to the IP will be 
summarized for each treatment group for the DBTP.
The incidence of common (≥ 2% of patients in any treatment group) TEAEs and NEAEs 
during the DBTP will be summarized by preferred term and treatment group and will be 
sorted by decreasing frequency for the weekly rapastinel group. 
An SAE that occurred between the date of the first dose of the open-label IP and 30 days 
after the date of the last dose of double-blind IP, inclusive, will be considered an on-
therapy SAE. The number and percentage of patients who had on-therapy SAEs during 
the OLTP will be summarized by preferred term and sorted by decreasing frequency. The 
number and percentage of patients who had on-therapy SAEs during the DBTP will be 
summarized by treatment group and preferred term and will be sorted by decreasing 
frequency for the weekly rapastinel group.
The number and percentage of patients who had fatal on-therapy SAEs during the OLTP
will be summarized by preferred term and sorted by decreasing frequency. The number 
and percentage of patients who had fatal on-therapy SAEs during the DBTP will be 
summarized by treatment group and preferred term and sorted by decreasing frequency 
for the weekly rapastinel group.
The incidence of TEAEs leading to premature discontinuation of IP during the OLTP will 
be summarized by preferred term and will be sorted by decreasing frequency. The 
incidence of TEAEs and NEAEs leading to premature discontinuation of IP during the 
DBTP will be summarized by preferred term and treatment group and will be sorted by 
decreasing frequency for the weekly rapastinel group.
Listings will be presented for all patients with SAEs, patients with AEs leading to 
discontinuation, and patients who died (if any).


Naurex, Inc.
84
RAP-MD-33 Protocol Final
02 May 2018
9
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
3
 
 
 
 
 
 
 
 
 
 
 
 


Naurex, Inc.
85
RAP-MD-33 Protocol Final
02 May 2018
 
9
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
5
 
 
 
 
 


Naurex, Inc.
86
RAP-MD-33 Protocol Final
02 May 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7.9
Interim Analysis
No interim analysis is planned for this study. 


Naurex, Inc.
87
RAP-MD-33 Protocol Final
02 May 2018
9.7.10
Determination of Sample Size
The sample size and power calculations are based on the analysis of time to relapse 
during the 52 weeks of the DBTP. Assuming a relapse rate of 19% per 26 weeks in the 
placebo group and a dropout rate of 20% per 26 weeks in all treatment groups, the sample 
size of 200 per group will have 90% power to detect a hazard ratio of 0.475 for a
rapastinel treatment versus placebo at a 0.05 significance level. To achieve this number 
of randomized patients, approximately 1400 patients need to be enrolled in this study if 
50% of patients are qualified for randomization.
9.7.11
Statistical Software
Statistical analyses will be performed using version 9.3 (or newer) of SAS.
9.8
DATA AND SAFETY MONITORING BOARD
The study will be conducted under the supervision of an independent DSMB to be 
chartered to review safety data at predetermined points during the study. The DSMB may 
also decide to meet and review safety data at other time points should it be deemed 
necessary. The DSMB is responsible for the ongoing review of safety data in the clinical 
study and for making recommendations concerning the continuation, modification, and 
termination of the study (FDA Guidance for Clinical Trial Sponsors: Establishment and 
Operation of Clinical Trial Data Monitoring Committees, March 2006; European 
Medicines Agency Guideline on Data Monitoring Committees, 
EMEA/CHMP/EWP/5872/03, July 2005).
All analyses that are required to support the DSMB will be performed by independent
statistician(s) not otherwise involved in the study. Details of the DSMB membership, 
meeting schedule, and data review and analysis will be documented in the DSMB 
Charter.
9.9
CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED 
ANALYSES
Any amendment to this protocol will be provided to the investigator in writing by the 
sponsor. No protocol amendment may be implemented (with the exceptions noted below) 
before it has been approved by the IRB/EC and other applicable oversight bodies and the 
signature page, signed by the investigator, and has been received by the sponsor. If the 
protocol is amended to eliminate or reduce the risk to patients, the amendment may be 
implemented before IRB/EC review and approval in jurisdictions where regulatory 
authorities allow such implementation. However, the IRB/EC must be informed in 
writing of such an amendment, and approval must be obtained within reasonable time 
limits. 


Naurex, Inc.
88
RAP-MD-33 Protocol Final
02 May 2018
If unclarities arise with regard to interpretation or conduct of the approved protocol 
during the conduct of the study, the sponsor will provide guidance in the form of a 
protocol clarification letter.  Such guidance will be used to clarify only within the bounds 
of the approved protocol.
9.10
PROTOCOL DEVIATIONS
A protocol deviation is any change, divergence, or departure from the study design or 
procedures that is under the investigator’s responsibility and oversight (as defined by 
regulations) without prior written IRB/EC approval or favorable opinion of an 
appropriate amendment and that does not have a major impact on the patient’s rights, 
safety, or well-being, or on the integrity and authenticity of the study data. Deviations 
may include, but are not limited to, departure from inclusion/exclusion criteria, dosing, 
duration of treatment, failure to perform the required assessments at specified time points, 
scheduling of visits not in accordance with specifications, or patient safety. Deviating 
from the protocol is permitted only if absolutely necessary for the safety or clinical 
management of the patients and must immediately be reported to the sponsor.
A significant protocol deviation is a form of protocol deviation that has a major impact 
on the patient’s rights, safety, or well-being, or on the integrity and authenticity of the 
study data. The IRB/EC must be notified within the time period dictated by the IRB/EC
associated with this study. 


Naurex, Inc.
89
RAP-MD-33 Protocol Final
02 May 2018
10.0
STUDY SPONSORSHIP
This study is sponsored by Naurex, Inc., an indirect subsidiary of Allergan, plc. 
10.1
STUDY TERMINATION
The sponsor reserves the right to terminate the study in its entirety or at a specific study 
center before study completion. 
10.2
REPORTING AND PUBLICATION
All data generated in this study are the property of the sponsor. An integrated clinical and 
statistical report will be prepared at the completion of the study.
Publication of the results by the investigator will be subject to mutual agreement between 
the investigator and the sponsor and will follow the sponsor’s Standard Operating 
Procedure on publications.


Naurex, Inc.
90
RAP-MD-33 Protocol Final
02 May 2018
11.0
INVESTIGATOR OBLIGATIONS
11.1
DOCUMENTATION
The following must be in place and filed with the sponsor before the start of the study at 
each study center:

A completed and signed Form FDA 1572 (for investigators in the US) or 
Investigator’s Information & Agreement in lieu of FDA 1572 (for investigators 
outside the US). If, during the course of the study, any changes are made that are not 
reflected on Form FDA 1572 or Investigator’s Information & Agreement in lieu of 
FDA 1572, a new Form FDA 1572 or Investigator’s Information & Agreement in lieu 
of FDA 1572 must be completed and returned to the sponsor

A fully executed contract

The curricula vitae for the investigator and all subinvestigators listed on Form FDA 
1572 or Investigator’s Information & Agreement in lieu of FDA 1572, including a 
copy of each physician’s license

A copy of the original IRB/EC approval for conducting the study. If the study is 
ongoing, renewals must be submitted at yearly intervals. All subsequent 
modifications must be submitted and approved by the IRB/EC, as stated in 
Section 5.1.

A copy of the IRB/EC-approved ICF

A copy of the HIPAA authorization form, or other applicable local privacy forms

A list of the IRB/EC members or the US Department of Health and Human Services 
general assurance number

A copy of the laboratory certifications and reference ranges

The investigator’s Statement page in this protocol signed and dated by the 
investigator

Investigators and subinvestigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory 
authorities. Investigators are responsible for providing information on financial 
interests during the course of the study and for 1 year after completion of the study.


Naurex, Inc.
91
RAP-MD-33 Protocol Final
02 May 2018
11.2
PERFORMANCE
The investigator must demonstrate reasonable efforts to obtain qualified patients for the 
study.
11.3
USE OF INVESTIGATIONAL MATERIALS
The investigator will acknowledge that the IP supplies are investigational and as such 
must be used strictly in accordance with the protocol and only under the supervision of 
the investigator or subinvestigators listed on Form FDA 1572 (or equivalent). The IP
must be stored in a secured place and must be locked. At study initiation, a representative 
from the sponsor will inventory the IP at the study center. The investigator must maintain 
adequate records documenting the receipt and disposition of all study supplies. The 
sponsor will supply forms on which to record the date the IP was received and a 
dispensing record in which to record each patient’s use. All unused IP must be returned to 
the sponsor. 
11.4
CASE REPORT FORMS
All patient data relating to the study will be recorded on eCRFs to be provided by the 
sponsor through the EDC system. The investigator is responsible for verifying that all 
data entries in the eCRFs are accurate and correct by electronically signing the completed 
eCRF casebook submitted to the sponsor. The investigator must maintain and retain 
accurate documentation that supports the information entered into the EDC system for 
source document verification and possible regulatory inspection.
11.5
RETENTION AND REVIEW OF RECORDS
Records and documents pertaining to the conduct of this study, including eCRFs, source 
documents, consent forms, regulatory documents, clinical laboratory results, calibration 
logs, or reports (including, but not limited to, all local and central laboratory results and 
ECG reports), and medication inventory records in all formats (including, but not limited 
to, written, electronic, magnetic, and optical records, and scans, x-rays, and ECGs) must 
be retained by the investigator for a period of at least 15 years after study completion 
unless local regulations or institutional policies require a longer retention period or 
otherwise notified in writing by the sponsor. 
No study records shall be destroyed without notifying the sponsor and providing the 
sponsor the opportunity to arrange long-term storage for such study records or 
authorizing in writing the destruction of records after the required retention period.


Naurex, Inc.
92
RAP-MD-33 Protocol Final
02 May 2018
The investigator must permit access to any documentation relating to the study upon 
request of the sponsor or applicable regulatory authorities. If the investigator for the study 
retires, relocates, or for other reasons withdraws from the responsibility of keeping the 
study records, custody must be transferred to a suitable alternate custodian employee of 
the institution or to a suitably qualified and responsible third party. The sponsor must be 
notified in writing of the name and address of the new custodian in advance of the 
transfer.
11.6
PATIENT CONFIDENTIALITY

Participants will be assigned a unique identifier (PID). Any participant records or 
datasets that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred. 

The participant must be informed that his/her personal study-related data will be used 
by the sponsor in accordance with local data protection law. The level of disclosure 
must also be explained to the participant. 

The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.


Naurex, Inc.
93
RAP-MD-33 Protocol Final
02 May 2018
12.0
INVESTIGATOR’S STATEMENT
I agree to conduct the study in accordance with this protocol (RAP-MD-33, dated 02 May 
2018) and with all applicable government regulations and good clinical practice 
guidance.
_______________________________________
_____/_____/______
Investigator’s Signature
Date
_______________________________________
Investigator’s Name


Naurex, Inc.
94
RAP-MD-33 Protocol Final
02 May 2018
13.0
APPENDICES
APPENDIX I.
ELEMENTS OF INFORMED CONSENT
Procedures will comply with 21 CFR, Parts 50 and 312, local regulations, ICH 
guidelines, HIPAA requirements, where applicable, and the IRB/IEC or study center. 
Signed informed consent will be obtained from each patient participating in a clinical 
research study. This consent must include the following items:

A statement that the study involves research and an explanation of the purposes of the 
research; a description of the procedures to be followed and the identification of any 
procedures that are experimental; and the expected duration of the patient’s 
participation

A description of any reasonably foreseeable risks or discomforts to the patient

A description of any benefits to the patient or to others that may reasonably be 
expected from the research. If the patient is to be paid for participating in the study, 
the consent form must state the amount that he/she will receive and the schedule of 
payment (to ensure neither coercion nor undue influence)

A disclosure of appropriate alternative procedures or courses of treatment, if any, that 
might be advantageous to the patient

A statement describing the extent, if any, to which confidentiality of records 
identifying the patient will be maintained and noting the possibility that the FDA, the 
sponsor, the IRB/EC, or an authorized contract research organization may inspect the 
records

For research involving more than minimal risk, an explanation of whether any 
medical treatment is available if injury occurs and, if so, what it consists of or where 
further information may be obtained

An explanation of whom to contact, including the relevant telephone number, for 
answers to pertinent questions about the research and the research patient’s rights and 
whom to contact in the event of a research-related injury to the patient. (Note: In 
some cases, it may be necessary to identify a person other than the investigator as the 
contact. The guidance of the IRB/EC may be required)

A statement that participation is voluntary, that refusal to participate will involve no 
penalty or loss of benefits to which the patient is otherwise entitled, and that the 
patient may discontinue participation at any time without penalty or loss of benefits to 
which the patient is otherwise entitled


Naurex, Inc.
95
RAP-MD-33 Protocol Final
02 May 2018

A statement that the particular treatment or procedures may involve risks to the 
patient (or to the embryo or fetus if the patient is, or may become, pregnant) that are 
at present unforeseeable

The expected circumstances for which the patient’s participation may be terminated 
by the investigator without regard to the patient’s consent

Any additional costs to the patient that may result from participation in the research

The consequences of a patient’s decision to withdraw from the research and 
procedures for an orderly termination of the patient’s participation

A statement that significant new findings developed during the course of the research 
that may relate to the patient’s willingness to continue participation will be provided 
to the patient

The approximate number of patients involved in the study

A statement of permission, providing consent for the patient to participate (eg, “I 
agree to participate . . .”)

A place for the patient’s signature and date of signing the ICF

A statement indicating that information about this study has been, or will be, entered 
into a databank that is publicly accessible at www.ClinicalTrials.gov.
A copy of the signed consent form must be given to the patient.


Naurex, Inc.
96
RAP-MD-33 Protocol Final
02 May 2018
APPENDIX II.
CONTACT INFORMATION 
Contact information for the sponsor personnel is maintained in the Study Reference 
Manual.


Naurex, Inc.
97
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
98
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
99
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
100
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
101
RAP-MD-33 Protocol Final
02 May 2018


Naurex, Inc.
102
RAP-MD-33 Protocol Final
02 May 2018
APPENDIX IV.
SCALES AND QUESTIONNAIRES
Please refer to the Study Reference Manual for reference copies of scales and 
questionnaires.


Naurex, Inc.
103
RAP-MD-33 Protocol Final
02 May 2018
14.0
LITERATURE CITED
American Psychiatric Association (2013). Diagnostic and statistical manual of mental 
disorders: DSM-5. Washington, DC: American Psychiatric Association
Ashton AK, Jamerson BD, Weinstein W, et al. Antidepressant-related adverse effects 
impacting treatment compliance: Results of a patient survey. Current Therapeutic 
Research, Clinical and Experimental 2005;66(2):96-
106.doi:10.1016/j.curtheres.2005.04.006.
Boland RJ, Keller MB. Treatment of depression. In: Schatzberg AF, Nemeroff CB, 
editors. Essentials of clinical psychopharmacology. 2nd ed. Arlington, VA: American 
Psychiatric Publishing, Inc.; 2006. p 465-478.
Borges S, Chen Y-F, Laughren TP, et al.  Review of maintenance trials for major 
depressive disorder: a 25-year perspective from the US Food and Drug Administration.  J 
Clin Psychiatry 2014:75;3:205-214.
Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the 
Clinician Administered Dissociative States Scale (CADSS). J Trauma Stress 
1998;11:125–136.
Clayton AH, McGarvey EL, and Clavet GJ.  The Changes in Sexual Functioning 
Questionnaier (CSFQ): development, reliability, and validity.  Psychopharacol Bull 
1997;33(4):731-743.
EMA/CHMP/185423/2010 Rev. 2 previously (CPMP/EWP/518/97, Rev. 1) Committee 
for Medicinal Products for Human Use (CHMP) 30 May 2013 Guideline on clinical 
investigation of medicinal products in the treatment of depression
Fava M and Davidson K. Definition and epidemiology of treatment-resistant depression. 
Psychiatr Clin North Am. 1996 Jun;19(2):179-200.
FDA Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial 
Data Monitoring Committees, March 2006 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf
FDA Guidance for Industry: Drug Induced Liver Injury- Pre-Marketing Clinical 
Evaluation, July 2009
FDA Guidance for Industry: E10, Choice of Control Group and Related Issues in 
Clinical Trials, May 2001


Naurex, Inc.
104
RAP-MD-33 Protocol Final
02 May 2018
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in 
the United States: how did it change between 1990 and 2000? J Clin Psychiatry 
2003;64(12):1465-1475.
Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test 
battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006 Oct;21(7):623-643.
Guy W: ECDEU Assessment Manual for Psychopharmacology - Revised, in 
(ed DHEW Publ No ADM 76-338). Rockville, MD, U.S., U.S. Department of Health, 
Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health 
Administration, NIMH Psychopharmacology Research Branch, Division of Extramural 
Research Programs, 1976;pp 218-222.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20 (10):1727-1736.
Keller A, McGarvey EL, and Clayton AH. Reliability and construct validity of the 
Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). Journal of Sex 
and Marital Therapy 2006;32:43-52.
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-
III-R psychiatric disorders in the United States: results from the National Comorbidity 
Study. Arch Gen Psychiatry 1994;51:8-19.
Kessler RC, Chiu WJ, Demler O, et al. Prevalence, severity, and comorbidity of 12-
month DSM-IV disorders in the National Comorbidity Survey. Arch Gen Psychiatry 
2005;62(6): 617-627.
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 
2003;25(8):2289-304.
McIntyre RS and Donovan C. The human cost of not achieving full remission in 
depression. Can J Psychiatry 2004;49(suppl 1):10S-16S.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. 
Br J Psychiatry 1979; 134:382-389.
Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of 
diseases, injuries, and risk factors. JAMA 2013;310(6):591-608.
Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA 
antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 
2015;172(10):950-966.


Naurex, Inc.
105
RAP-MD-33 Protocol Final
02 May 2018
Overall JE and Gorham DR. The brief psychiatric rating scale. Psychological Reports 
1962;10:799-812.
Rapastinel: Investigator’s Brochure. Edition 7. Evanston, IL: Naurex, Inc; 01 Jul 2014. 
Rosenzweig-Lipson S, Beyer CG, Hughes ZA, et al. Differentiating antidepressants of 
the future: efficacy and safety. Pharmacol Ther 2007;113(1):134-153.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in 
depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J 
Psychiatry 2006;163:1905-1917.
Sheehan DV, Sheeha KH, and Raj BA.  The measurement of disability. International 
Clinical Psychopharmacology 1996;11 (suppl 3):89-95.
Smith DW and Jones KL (1982). Recognizable Patterns of Human Malformation. (3 ed.) 
Philadelphia: Saunders.
Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentations after the failure of 
SSRIs for depression. N Engl J Med 2006;354(12):1243-1252.
Videbech P and Ravnkilde B. Hippocampal volume and depression: a meta-analysis of 
MRI studies. Am J Psychiatry 2004;161:1957-1966.
Williams JA and Kobak KA.  Development and reliability of a structured interview guide 
for the Montgomery-Åsberg Depression Rating Scale (SIGMA). The British Journal of 
Psychiatry 2008;192:52-58.
World Health Organization. Mental health: new understanding, new hope. World Health 
Report 2001.

SAP_001.pdf: 
NCT03614156 
 
Study ID: RAP‐MD‐33 
 
 
 
Title: A Randomized, Double‐blind, Placebo‐controlled, Multicenter Study of Rapastinel in the 
Prevention of Relapse in Patients with Major Depressive Disorder 
 
Statistical Analysis Plan Date: 26 Aug 2019 
 
 


 
 
RAP-MD-33  
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel 
in the Prevention of Relapse in Patients with Major Depressive Disorder 
STATISTICAL ANALYSIS PLAN  
SAP Date: August 26, 2019 
 
 
 
 
 
 
 
 
 
 
 
 
Confidentiality Statement 
This document is the property of Forest Research Institute, Inc., (a wholly owned 
subsidiary of Forest Laboratories, Inc.) and may notin full or partbe passed on, 
reproduced, published, distributed to any person, or submitted to any regulatory 
authority without the express written permission of Forest Laboratories, Inc. 


Allergan PLC 
 
Page 2 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
TABLE OF CONTENTS 
TABLE OF CONTENTS ................................................................................................................................ 2 
1.0 
LIST OF ABBREVIATIONS ........................................................................................................... 4 
2.0 
INTRODUCTION ............................................................................................................................ 6 
3.0 
OBJECTIVES ................................................................................................................................. 14 
4.0 
PATIENT POPULATIONS ............................................................................................................ 16 
4.1 
Open-label Safety Population ........................................................................................... 16 
4.2 
Open-label Modified Intent-to-Treat Population .............................................................. 16 
4.3 
Double-Blind Safety Population ....................................................................................... 16 
4.4 
Double-Blind Modified Intent-to-Treat Population .......................................................... 16 
5.0 
PATIENT DISPOSITION .............................................................................................................. 17 
6.0 
DEMOGRAPHICS AND BASELINE CHARACTERISTICS ...................................................... 18 
7.0 
EXTENT OF EXPOSURE AND TREATMENT COMPLIANCE ................................................ 19 
7.1 
Extent of Exposure ........................................................................................................... 19 
8.0 
EFFICACY ANALYSES ............................................................................................................... 20 
8.1 
Primary Efficacy Parameters ............................................................................................ 20 
 
 
9.0 
SAFETY ANALYSES .................................................................................................................... 21 
9.1 
Adverse Events ................................................................................................................. 21 
 
 
 
 
 
 
 
 
 
 
11.0 
INTERIM ANALYSIS ................................................................................................................... 28 
12.0 
DETERMINATION OF SAMPLE SIZE ....................................................................................... 29 
13.0 
STATISTICAL SOFTWARE ......................................................................................................... 30 
14.0 
DATA HANDLING CONVENTIONS .......................................................................................... 31 
14.1 
Summary Statistics ........................................................................................................... 31 
14.2 
Visit Time Windows ......................................................................................................... 31 
14.3 
Derived Variables ............................................................................................................. 37 
14.4 
Repeated or Unscheduled Assessments of Safety Parameters .......................................... 38 
14.5 
Missing Severity Assessment for Adverse Events ............................................................ 38 
14.6 
Missing Causal Relationship to study drug for Adverse Events ....................................... 38 
14.7 
Missing Date Information for Adverse Events ................................................................. 38 


Allergan PLC 
 
Page 3 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
14.8 
Missing Date Information for Prior or Concomitant Medications .................................... 40 
14.8.1 
Incomplete Start Date ......................................................................................... 40 
14.8.2 
Incomplete Stop Date ......................................................................................... 41 
14.9 
Character Values of Clinical Laboratory Parameters ........................................................ 42 
14.10 
Actual Treatment For Analysis ......................................................................................... 43 
14.11 
Stratification Handling Conventions ................................................................................. 43 
15.0 
CHANGES TO ANALYSES SPECIFIED IN PROTOCOL .......................................................... 44 
 


Allergan PLC 
 
Page 4 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
1.0 
LIST OF ABBREVIATIONS  
ADT 
antidepressant therapy 
AE 
adverse event 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
β-hCG  
β-human chorionic gonadotropin 
BP 
blood pressure 
 
 
 
 
 
 
CI 
confidence interval 
CRF 
case report form 
 
 
 
 
DBTP 
double-blind treatment period 
ECG 
electrocardiogram, electrocardiographic 
ET 
early termination 
ICF 
informed consent form 
IP 
investigational product 
IV 
intravenous 
IWRS 
Interactive Web Response System 
ITT 
intent-to-treat 
  
 
MDD  
major depressive disorder 
NEAE  
newly emergent adverse event 


Allergan PLC 
 
Page 5 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
PCS 
potentially clinically significant 
PID 
patient identification 
QTc 
QT interval corrected for heart rate 
QTcB 
QT interval corrected for heart rate using the Bazett formula 
(QTcB = QT/(RR)½) 
QTcF 
QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/(RR)⅓) 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
 
 
  
 
SE 
standard error 
SOC  
system organ class 
SI 
Le Système International d’Unités (International System of Units) 
T3  
 
 
triiodothyronine 
T4  
thyroxine 
TEAE 
treatment-emergent adverse event 
UDS  
urine drug screen 
ULN  
upper limit of normal 


Allergan PLC 
 
Page 6 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
2.0 
INTRODUCTION 
This Statistical Analysis Plan (SAP) describes the methodology that will be used to 
summarize the statistical analyses of the efficacy and safety data for the final protocol of 
Study RAP-MD-33 (version dated 02MAY2018).  
Study RAP-MD-33 is a Phase 3, multicenter, randomized-withdrawal, parallel-group, 
placebo-controlled, maintenance study to evaluate the efficacy, safety, and tolerability of 
rapastinel in the prevention of relapse in patients with major depressive disorder (MDD) 
who completed one of the rapastinel lead-in studies including RAP-MD-30 and RAP-
MD-32.  The RAP-MD-31 study was terminated before any patient was enrolled.  Thus, 
there is no patient rolled-over from the RAP-MD-31 study to RAP-MD-33 study.  
The study will be conducted in the following periods: 
 An 8- to 16-week open-label treatment period (OLTP) where patients receive 
rapastinel 225 or 450 mg IV weekly 
 A randomized double-blind treatment period (DBTP) of at most 52 weeks of 
treatment duration where patients are randomized 1:1:1 to either rapastinel 225 or 450 
mg weekly, rapastinel clinically driven schedule (IV, 225 or 450 mg, variable 
interval, placebo on intervening weeks) or placebo 
 A 2-week safety follow-up period 
In order for patients to transition from the OLTP and be randomized into the DBTP, the 
patient must meet the stability criterion sometime after 8 weeks (and up to 16 weeks) 
during the OLTP.  A patient will be considered a stable responder upon achieving both 
criteria (1) and (2) below: 
1) An observed Montgomery-Asberg Depression Rating Scale (MADRS) total score 
≤ 12 with no more than one modest MADRS excursion (MADRS total score > 12 
but ≤ 16) for at least six consecutive weeks.   
2) An observed MADRS total score ≤ 12 for at least two consecutive visits prior to 
randomization.   
The OLTP starts with the first dose of open-label treatment and ends with one of the 
following: the first dose of double-blind treatment for patients who enter the DBTP or 
Visit 69/Week 52 End-of-Treatment/Early Termination (ET) assessments for patients 
who do not enter the DBTP. 
The double-blind treatment period starts when the first dose of double-blind treatment is 
administered and ends when the patient meets relapse criteria, completes 52 weeks of 
double-blind treatment, or discontinues for other reasons. 


Allergan PLC 
 
Page 7 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
The safety follow-up (SFU) period starts after completion of the last scheduled 
assessment (or ET) and ends with the last available assessment. 
Individual treatment durations will vary. The maximum duration of the study will be 
70 weeks.


RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 10 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 11 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 12 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 13 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


3.0 
OBJECTIVES 
 The objective of this study is to evaluate the efficacy, safety, and tolerability of 
rapastinel relative to placebo in the prevention of relapse in patients with MDD.   
Efficacy Objectives 
 Primary efficacy objective: To evaluate the efficacy of rapastinel (225 or 450 mg IV 
weekly or clinically driven schedule) versus placebo in the maintenance treatment of 
MDD as a monotherapy, as measured by time to relapse during the first 52 weeks of 
the DBTP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allergan PLC 
 
Page 15 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allergan PLC 
 
Page 16 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
4.0 
PATIENT POPULATIONS 
The following analysis populations will be considered in the statistical analysis of the 
study. 
4.1 
OPEN-LABEL SAFETY POPULATION 
The Open-label Safety Population will consist of all patients who signed the informed 
consent form (ICF) and received at least 1 dose of open-label rapastinel during the OLTP 
of the study. 
4.2 
OPEN-LABEL MODIFIED INTENT-TO-TREAT POPULATION 
The Open-label modified Intent-to-Treat (OL mITT) Population will consist of all 
patients in the Open-label Safety Population who had at least 1 postbaseline assessment 
of the MADRS during the OLTP of the study. An assessment is considered postbaseline 
in the OLTP if it was taken after the first dose of open-label rapastinel during the OLTP 
of the study. 
4.3 
DOUBLE-BLIND SAFETY POPULATION 
The Double-blind Safety Population will consist of all patients in the Open-label Safety 
Population who were randomized to a treatment group during the DBTP of the study and 
received at least 1 dose of double-blind IP. 
4.4 
DOUBLE-BLIND MODIFIED INTENT-TO-TREAT POPULATION 
The Double-blind modified Intent-to-Treat (DB mITT) Population will consist of all 
patients in the Double-blind Safety Population who had at least 1 post-randomization 
assessment of the MADRS or the CGI-S during the DBTP of the study. 


Allergan PLC 
 
Page 17 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
5.0 
PATIENT DISPOSITION 
The number of patients who were screened for participation in the OLTP from lead-in 
studies RAP-MD-30 and RAP-MD-32, and who were screen failures and reasons for 
failing will be summarized. 
The number of patients in the Open-label Safety and Open-label mITT Populations will 
be summarized overall and by study center. The number of patients in the Double-blind 
Safety and Double-blind mITT Populations will be summarized overall, and by treatment 
group by study center. 
The number and percentage of patients who entered the OLTP, who prematurely 
discontinued from the OLTP, who completed the OLTP, who met or did not meet the 
criteria to enter the DBTP at the end of the OLTP, and who entered the DBTP will be 
summarized overall and by reasons for premature discontinuation for all enrolled patients 
in the OLTP.  
Similarly, the number and percentage of patients who completed the DBTP and who 
prematurely discontinued from the DBTP will be summarized overall, by double-blind 
treatment group, and by reasons for premature discontinuation for the all randomized 
patients in the DBTP. 


Allergan PLC 
 
Page 18 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
6.0 
DEMOGRAPHICS AND BASELINE CHARACTERISTICS 
Demographic parameters (e.g., age, race, ethnicity, sex,) and baseline characteristics 
(e.g., weight, height, body mass index) will be summarized overall for the Open-label 
mITT Populations and by treatment group for the Double-blind modified ITT population.  
Medical and surgical history during the past 12 months and psychotropic medication 
history during the previous 5 years will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), version 21.0 or newer. Data will be presented in 
listings for the Open-label Safety Population. 
Psychiatric history will be summarized overall for the Open-label mITT Populations and 
by treatment group for the Double-blind modified ITT population. 
Prior medication is defined as any medication started before the date of first dose of 
open-label IP. Concomitant medication during the OLTP is defined as any medication 
taken on or after the date of the first dose of open-label IP during the OLTP. Concomitant 
medication during the DBTP will be defined as any medication taken on or after the date 
of the first dose of double-blind IP. 
Prior and concomitant medications during the OLTP will be listed for the Open-label 
Safety Population. Concomitant medications during the DBTP will be listed for the 
Double-blind Safety Population. Concomitant medications started after the patient’s last 
study visit during their last treatment period will be presented in the data listings. 
The World Health Organization Drug Dictionary Enhanced (WHODDE) will be used to 
classify prior and concomitant medications by therapeutic class and drug name. 


Allergan PLC 
 
Page 19 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
7.0 
EXTENT OF EXPOSURE AND TREATMENT COMPLIANCE 
7.1 
EXTENT OF EXPOSURE 
Exposure to open-label rapastinel for the Open-label Safety Population during the OLTP 
will be summarized for treatment duration, calculated as the number of days from the 
date of the first dose of open-label rapastinel taken to the date of the last dose taken 
during the OLTP, inclusive. Descriptive statistics will be presented. 
Exposure to double-blind IP for the Double-blind Safety Population during the DBTP 
will be summarized for treatment duration, calculated as the number of days from the 
date of the first dose of double-blind IP taken to the date of the last dose taken during the 
DBTP, inclusive. Descriptive statistics will be presented by treatment group. 
The number of IV doses of rapastinel administered to each patient during the OLTP will 
be summarized using descriptive statistics for the Open-label Safety Population.  
Similarly, the number of IV doses administered to each patient during the DBTP will be 
summarized by treatment group, using descriptive statistics for the Double-Blind Safety 
Population. 


Allergan PLC 
 
Page 20 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
8.0 
EFFICACY ANALYSES 
8.1 
PRIMARY EFFICACY PARAMETERS 
The analysis of the primary efficacy parameter will be performed using the Double-blind 
mITT Population.  
The primary efficacy parameter is the time to first relapse during the 52 weeks of the 
DBTP, defined as the number of days from the randomization date of DBTP to the 
relapse date (ie., relapse date – randomization date + 1). Relapse during the DBTP is 
defined as meeting any of the following criteria: 
 Rater-administered MADRS total score ≥ 18 at 2 consecutive visits 
 ≥ 2 increase in CGI-S score compared with that obtained at randomization 
 Risk of suicide as determined by the investigator 
 Need for hospitalization due to worsening of depression as determined by the 
investigator 
 Need for alternative treatment of depressive symptoms as determined by the 
investigator 
Patients who did not meet the above relapse criteria during the 52 weeks of the DBTP, 
the time to relapse will be censored at the time of completion or discontinuation from the 
study, or 52 weeks, whichever is earlier. 
The primary efficacy analysis will be presented by the cumulative distribution function of 
time to relapse characterized by the Kaplan-Meier curve for each treatment group. 
 
 
 


Allergan PLC 
 
Page 21 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
9.1 
ADVERSE EVENTS 
AEs will be coded using the Medical Dictionary for Regulatory Activities. 
An AE (classified by preferred term) that occurs during the OLTP or thereafter will be 
considered a treatment-emergent adverse event (TEAE) if it was not present before the 
date of the first dose of IP in the lead-in study or was present before the first dose of IP in 
the lead-in study and increased in severity during the OLTP or thereafter.  An AE that 
becomes serious during the OLTP or thereafter will also be considered as TEAE.  If more 
than 1 AE is reported before the date of the first dose of IP in the lead-in study and coded 
to the same preferred term, the AE with the greatest severity will be used as the 
benchmark for comparison with the AEs occurring during the OLTP or thereafter that 
were also coded to that preferred term.  An AE that occurs more than 30 days after the 
date of the last dose of IP will not be counted as a TEAE. 
An AE (classified by preferred term) that occurs during the OLTP of the study will be 
considered a newly emergent adverse event (NEAE) if the AE was not present before the 
first dose of IP in the OLTP or it was present before the first dose of IP in the OLTP and 
increased in severity during the OLTP.  An AE that becomes serious during the OLTP 
will also be considered as NEAE.  If more than 1 AE is reported before the first dose of 
IP in the OLTP and coded to the same preferred term, the AE with the greatest severity 
will be used as the benchmark for comparison with the AEs occurring during the OLTP 
that were also coded to that preferred term.  


Allergan PLC 
 
Page 22 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
An AE (classified by preferred term) that occurs during the DBTP of the study will be 
considered a newly emergent adverse event (NEAE) if the AE was not present before the 
first dose of IP in the DBTP or it was present before the first dose of IP in the DBTP and 
increased in severity during the DBTP.  An AE that becomes serious during the DBTP 
will also be considered as NEAE.  If more than 1 AE is reported before the first dose of 
IP in the DBTP and coded to the same preferred term, the AE with the greatest severity 
will be used as the benchmark for comparison with the AEs occurring during the DBTP 
that were also coded to that preferred term.  
An AE (classified by preferred term) that occurs during the SFU of the study will be 
considered a newly emergent adverse event (NEAE) if the AE was not present before or 
at Visit 70 or it was present before or at Visit 70 and increased in severity during the 
SFU. An AE that becomes serious during the SFU will also be considered as NEAE. If 
more than 1 AE is reported before or at Visit 70 and coded to the same preferred term, 
the AE with the greatest severity will be used as the benchmark for comparison with the 
AEs occurring during the SFU that were also coded to that preferred term.  
An AE that occurs more than 30 days after the date of the last dose of IP will not be 
counted as an NEAE. 
An SAE that occurred between the date of the first dose of IP in the OLTP and 30 days 
after the date of the last dose of IP, inclusive, will be considered a treatment-emergent 
SAE (e.g., TESAE). 
The overall number and percentage of patients with TEAEs, NEAEs, death, TESAEs, 
TEAEs leading to study discontinuation and TEAEs related to study drug during the 
OLTP will be tabulated overall, and during the DBTP and the SFU by treatment group. 
The incidence of common (≥ 2% of patients in any treatment group) TEAEs and NEAEs 
during the OLTP will be summarized overall by preferred term.  Similarly, the incidence 
of common TEAEs and NEAEs during the DBTP and during the SFU will be 
summarized by preferred term and treatment group and will be sorted by decreasing 
frequency starting with the weekly rapastinel group followed by the clinically driven 
schedule rapastinel group.  
Listings will be presented for all patients with AEs and patients who died (if any). 
 
 
 
 


Allergan PLC 
 
Page 23 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 24 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 25 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 26 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 


Allergan PLC 
 
Page 27 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 
 
 
 


Allergan PLC 
 
Page 28 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
11.0 
INTERIM ANALYSIS 
No interim analysis is planned for this study. 


Allergan PLC 
 
Page 29 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
12.0 
DETERMINATION OF SAMPLE SIZE 
The sample size and power calculations are based on the analysis of time to relapse 
during the first 52 weeks of the DBTP. Assuming a relapse rate of 19% per 26 weeks in 
the placebo group and a dropout rate of 20% per 26 weeks in all treatment groups, the 
sample size of 200 per group will have 90% power to detect a hazard ratio of 0.475 for a 
rapastinel treatment versus placebo at a 0.05 significance level. To achieve this number 
of randomized patients, approximately 1400 patients need to be enrolled in this study if 
50% of patients are qualified for randomization. 


Allergan PLC 
 
Page 30 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
13.0 
STATISTICAL SOFTWARE 
Statistical analyses will be performed 
 


Allergan PLC 
 
Page 31 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
14.0 
DATA HANDLING CONVENTIONS 
14.1 
SUMMARY STATISTICS 
The following statistical summaries will be presented for each type of data: 
- 
Continuous variables will be summarized by descriptive statistics (number of 
patients, mean, standard deviation (SD), median, minimum, and maximum 
values).  
- 
Categorical variables will be summarized by frequency distributions (counts and 
percentages). 
- 
Time-to-event data will be summarized by showing the number of patients, 
number of patients experiencing the event of interest, estimates of the median, 
first quartile and third quartile using the Kaplan Meier estimate as well as a 95% 
CI for the median 
14.2 
VISIT TIME WINDOWS 
Tables 15.2–1 and 15.2–2 present visits assigned for efficacy and safety analyses and the 
corresponding range of treatment days (window) during which an actual visit may occur 
for the OLTP and DBTP respectively. 
Table 14.2–1. 
OLTP Visit Time Windows 
Derived Visit Target Day 
Analysis Visit Window 
Baseline 
 
<= Day 0 a 
Open-label Treatment Period (OLTP) 
Day 1 
Day 1 
Day 1 
Day 7 
Day 7 
Start: Day 2  
End: the Day 7 dosing (Visit 2) date or Day 10 (if no Day 7 dosing)b 
Week 2 
Day 14 
Start: 1 day after the Day 7 window ends  
End: the Week 2 (Visit 3) dosing date or Day 17 (if no Week 2 dosing)b 
Week 3 
Day 21 
Start: 1 day after the Week 2 window ends  
End: the Week 3 (Visit 4) dosing date or Day 24 (if no Week 3 dosing) b 
Week 4 
Day 28 
Start: 1 day after the Week 3 window ends  
 
 
End: the Week 4 (Visit 5) dosing date or Day 31 (if no Week 4 dosing)b 
Week 5 
Day 35 
Start: 1 day after the Week 4 window ends 
 
 
End: the Week 5 (Visit 6) dosing date or Day 38 (if no Week 5 dosing)b 


Allergan PLC 
 
Page 32 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
Week 6 
Day 42 
Start: 1 day after the Week 5 window ends  
 
 
End: the Week 6 (Visit 7) dosing date or Day 45 (if no Week6 dosing)b 
Week 7 
Day 49 
Start: 1 day after the Week 6 window ends 
 
 
End: the Week 7 (Visit 8) dosing date or Day 52 (if no Week 7 dosing)b 
Week 8 
Day 56 
Start: 1 day after the Week 7 window ends 
 
 
End: the Week 8 (Visit 9) dosing date or Day 59 (if no Week 8 dosing)b 
Week 9 
Day 63 
Start: 1 day after the Week 8 window ends 
 
 
End: the Week 9 (Visit 10) dosing date or Day 66 (if no Week 9 dosing)b 
Week 10 
Day 70 
Start: 1 day after the Week 9 window ends 
 
 
End: the Week 10 (Visit 11) dosing date or Day 73 (if no Week 10 dosing)b 
Week 11 
Day 77 
Start: 1 day after the Week 10 window ends 
 
 
End: the Week 11 (Visit 12) dosing date or Day 80 (if no Week 11 dosing)b 
Week 12 
Day 84 
Start: 1 day after the Week 11 window ends 
 
 
End: the Week 12 (Visit 13) dosing date or Day 87 (if no Week 12 dosing)b 
Week 13 
Day 91 
Start: 1 day after the Week 12 window ends 
 
 
End: the Week 13 (Visit 14) dosing date or Day 94 (if no Week 13 dosing)b 
Week 14 
Day 98 
Start: 1 day after the Week 13 window ends 
 
 
End: the Week 14 (Visit 15) dosing date or Day 101 (if no Week 14 dosing)b 
Week 15 
Day 105 
Start: 1 day after the Week 14 window ends 
 
 
End: the Week 15 (Visit 16) dosing date or Day 108 (if no Week 15 dosing)b 
Week 16 
Day 112 
Start: 1 day after the Week 15 window ends 
 
 
End: End of OLTP (Randomization Date or Date of Early Termination Visit)


Allergan PLC 
 
Page 33 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
Table 14.2–2. 
DBTP Visit Time Windows 
 
Derived Visit 
Target Day 
Analysis Visit Window 
Baseline 
 
<= Day/Week 0 a 
Double Blind Treatment Period (DBTP) 
Day 1 
Day 1 
Date of first dosing of IP in DBTP (Visit 17) 
Day 7 
Day 7 
Start: Day 2  
End: the Day 7 dosing (Visit 18) date or Day 10 (if no Day 7 dosing)b 
Week 2 
Day 14 
Start: 1 day after the Day 7 window ends  
End: the Week 2 (Visit 19) dosing date or Day 17 (if no Week 2 dosing)b 
Week 3 
Day 21 
Start: 1 day after the Week 2 window ends  
End: the Week 3 (Visit 20) dosing date or Day 24 (if no Week 3 dosing) b 
Week 4 
Day 28 
Start: 1 day after the Week 3 window ends  
 
 
End: the Week 4 (Visit 21) dosing date or Day 31 (if no Week 4 dosing)b 
Week 5 
Day 35 
Start: 1 day after the Week 4 window ends 
 
 
End: the Week 5 (Visit 22) dosing date or Day 38 (if no Week 5 dosing)b 
Week 6 
Day 42 
Start: 1 day after the Week 5 window ends 
 
 
End: the Week 6 (Visit 23) dosing date or Day 45 (if no Week 6 dosing)b 
Week 7 
Day 49 
Start: 1 day after the Week 6 window ends 
 
 
End: the Week 7 (Visit 24) dosing date or Day 52 (if no Week 7 dosing)b 
Week 8 
Day 56 
Start: 1 day after the Week 7 window ends 
 
 
End: the Week 8 (Visit 25) dosing date or Day 59 (if no Week 8 dosing)b 
Week 9 
Day 63 
Start: 1 day after the Week 8 window ends 
 
 
End: the Week 9 (Visit 26) dosing date or Day 66 (if no Week 9 dosing)b 
Week 10 
Day 70 
Start: 1 day after the Week 9 window ends 
 
 
End: the Week 10 (Visit 27) dosing date or Day 73 (if no Week 10 
dosing)b 
Week 11 
Day 77 
Start: 1 day after the Week 10window ends 
 
 
End: the Week 11 (Visit 28) dosing date or Day 80 (if no Week 11 
dosing)b 
Week 12 
Day 84 
Start: 1 day after the Week 11 window ends 
 
 
End: the Week 12 (Visit 29) dosing date or Day 87 (if no Week 12 
dosing)b 
Week 13 
Day 91 
Start: 1 day after the Week 12 window ends 
 
 
End: the Week 13 (Visit 30) dosing date or Day 94 (if no Week 13 
dosing)b 


Allergan PLC 
 
Page 34 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
Week 14 
Day 98 
Start: 1 day after the Week 13 window ends 
 
 
End: the Week 14 (Visit 31) dosing date or Day 101 (if no Week 14 
dosing)b 
Week 15 
Day 105 
Start: 1 day after the Week 14 window ends 
 
 
End: the Week 15 (Visit 32) dosing date or Day 108 (if no Week 15 
dosing)b 
Week 16 
Day 112 
Start: 1 day after the Week 15 window ends 
 
 
End: the Week 16 (Visit 33) dosing date or Day 115 (if no Week 16 
dosing)b 
Week 17 
Day 119 
Start: 1 day after the Week 16 window ends 
 
 
End: the Week 17 (Visit 34) dosing date or Day 122 (if no Week 17 
dosing)b 
Week 18 
Day 126 
Start: 1 day after the Week 17 window ends 
 
 
End: the Week 18 (Visit 35) dosing date or Day 129 (if no Week 18 
dosing)b 
Week 19 
Day 133 
Start: 1 day after the Week 18 window ends 
 
 
End: the Week 19 (Visit 36) dosing date or Day 136 (if no Week 19 
dosing)b 
Week 20 
Day 140 
Start: 1 day after the Week 19 window ends 
 
 
End: the Week 20 (Visit 37) dosing date or Day 143 (if no Week 20 
dosing)b 
Week 21 
Day 147 
Start: 1 day after the Week 20 window ends 
 
 
End: the Week 21 (Visit 38) dosing date or Day 150 (if no Week 21 
dosing)b 
Week 22 
Day 154 
Start: 1 day after the Week 21 window ends 
 
 
End: the Week 22 (Visit 39) dosing date or Day 157 (if no Week 22 
dosing)b 
Week 23 
Day 161 
Start: 1 day after the Week 22 window ends 
 
 
End: the Week 23 (Visit 40) dosing date or Day 164 (if no Week 23 
dosing)b 
Week 24 
Day 168 
Start: 1 day after the Week 23 window ends 
 
 
End: the Week 24 (Visit 41) dosing date or Day 171 (if no Week 24 
dosing)b 
Week 25 
Day 175 
Start: 1 day after the Week 24 window ends 
 
 
End: the Week 25 (Visit 42) dosing date or Day 178 (if no Week 25 
dosing)b 
Week 26 
Day 182 
Start: 1 day after the Week 25 window ends 
 
 
End: the Week 26 (Visit 43) dosing date or Day 185 (if no Week 26 
dosing)b 
Week 27 
Day 189 
Start: 1 day after the Week 26 window ends 


Allergan PLC 
 
Page 35 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 
 
End: the Week 27 (Visit 44) dosing date or Day 192 (if no Week 27 
dosing)b 
Week 28 
Day 196 
Start: 1 day after the Week 27 window ends 
 
 
End: the Week 28 (Visit 45) dosing date or Day 199 (if no Week 28 
dosing)b 
Week 29 
Day 203 
Start: 1 day after the Week 28 window ends 
 
 
End: the Week 29 (Visit 46) dosing date or Day 206 (if no Week 29 
dosing)b 
Week 30 
Day 210 
Start: 1 day after the Week 29 window ends 
 
 
End: the Week 30 (Visit 47) dosing date or Day 213 (if no Week 30 
dosing)b 
Week 31 
Day 217 
Start: 1 day after the Week 30 window ends 
 
 
End: the Week 31 (Visit 48) dosing date or Day 220 (if no Week 31 
dosing)b 
Week 32 
Day 224 
Start: 1 day after the Week 31 window ends 
 
 
End: the Week 32 (Visit 49) dosing date or Day 227 (if no Week 32 
dosing)b 
Week 33 
Day 231 
Start: 1 day after the Week 32 window ends 
 
 
End: the Week 33 (Visit 50) dosing date or Day 234 (if no Week 33 
dosing)b 
Week 34 
Day 238 
Start: 1 day after the Week 33 window ends 
 
 
End: the Week 34 (Visit 51) dosing date or Day 241 (if no Week 34 
dosing)b 
Week 35 
Day 245 
Start: 1 day after the Week 34 window ends 
 
 
End: the Week 35 (Visit 52) dosing date or Day 248 (if no Week 35 
dosing)b 
Week 36 
Day 252 
Start: 1 day after the Week 35 window ends 
 
 
End: the Week 36 (Visit 53) dosing date or Day 255 (if no Week 36 
dosing)b 
Week 37 
Day 259 
Start: 1 day after the Week 36 window ends 
 
 
End: the Week 37 (Visit 54) dosing date or Day 262 (if no Week 37 
dosing)b 
Week 38 
Day 266 
Start: 1 day after the Week 37 window ends 
 
 
End: the Week 38 (Visit 55) dosing date or Day 269 (if no Week 38 
dosing)b 
Week 39 
Day 273 
Start: 1 day after the Week 38 window ends 
 
 
End: the Week 39 (Visit 56) dosing date or Day 280 (if no Week 39 
dosing)b 
Week 40 
Day 280 
Start: 1 day after the Week 39 window ends 
 
 
End: the Week 40 (Visit 57) dosing date or Day 283 (if no Week 40 


Allergan PLC 
 
Page 36 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
dosing)b 
Week 41 
Day 287 
Start: 1 day after the Week 40 window ends 
 
 
End: the Week 41 (Visit 58) dosing date or Day 290 (if no Week 41 
dosing)b 
Week 42 
Day 294 
Start: 1 day after the Week 41 window ends 
 
 
End: the Week 42 (Visit 59) dosing date or Day 297 (if no Week 42 
dosing)b 
Week 43 
Day 301 
Start: 1 day after the Week 42 window ends 
 
 
End: the Week 43 (Visit 60) dosing date or Day 304 (if no Week 43 
dosing)b 
Week 44 
Day 308 
Start: 1 day after the Week 43 window ends 
 
 
End: the Week 44 (Visit 61) dosing date or Day 311 (if no Week 44 
dosing)b 
Week 45 
Day 315 
Start: 1 day after the Week 44 window ends 
 
 
End: the Week 45 (Visit 62) dosing date or Day 318 (if no Week 45 
dosing)b 
Week 46 
Day 322 
Start: 1 day after the Week 45 window ends 
 
 
End: the Week 46 (Visit 63) dosing date or Day 235 (if no Week 46 
dosing)b 
Week 47 
Day 329 
Start: 1 day after the Week 46 window ends 
 
 
End: the Week 47 (Visit 64) dosing date or Day 332 (if no Week 47 
dosing)b 
Week 48 
Day 336 
Start: 1 day after the Week 47 window ends 
 
 
End: the Week 48 (Visit 65) dosing date or Day 339 (if no Week 48 
dosing)b 
Week 52 
Day 364 
Start: 1 day after the Week 48 window ends 
 
 
End: End of DBTP (Visit 69, the study exit date of DBTP) 
Safety Follow-up Period (SFP) 
Week 54 
Day 378 
Within the safety follow-up phase (Visit 70) 
    End of SFP: Final or termination visit during SFP 
a Day 0 is the date of the first dose of study treatment; baseline is defined as the last non-missing observations prior to 
first dose of study treatment for the given treatment period.  
b Dosing visit is the nominal visit reported in CRF. During the OLTP a patient is scheduled to receive the 1st dose on 
day 0 (Visit 1), the 2nd dose at week 1, and will be weekly administered until week 16. If a patient skipped a 
scheduled re-treatment dosing at a week, the dosing date will be treated as missing for that week. During the DBTP 
a patient is schedule to receive the 1st dose on day 0 (Visit 17), the 2nd dose at week 1, and will be weekly 
administered until relapse criteria are met or for up to 52 weeks (Visit 69) or study termination. 
 
 


Allergan PLC 
 
Page 37 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
If a patient has 2 or more values for a given endpoint within the same window, the value 
with collection date closest to the scheduled day will be used for analysis; if there are 2 
values whose collection dates are equidistant from the scheduled day, the value 
corresponding to the later date will be used for analysis. 
With the exception of endpoints recorded pre or post IP dose and Visit 69/ET MADRS 
assessments, in the event there are multiple values of the same endpoint on the same date, 
the last value will be taken as the value for that date.  For endpoints reported pre IP dose, 
in the event there are multiple values of the same endpoint prior to IP dose, the last value 
prior to the IP dose is taken as the pre-dose value for that date.  Similarly, for endpoints 
reported post IP dose, in the event there are multiple values of the same endpoint after IP 
dose, the last value will be taken as the post-dose value for that date.  For multiple 
MADRS assessments on the same date for Visit 69/ET, the last MADRS assessment prior 
to Visit 69/ET on that date will be taken as the value for that date. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 


Allergan PLC 
 
Page 38 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 
 
 
 
 
 
The first relapse date for a patient is defined as the earliest assessment date in which any 
of the relapse criteria mentioned above were met, obtained either from the date recorded 
on the Relapse CRF (for the primary reasons of “Risk of Suicide”, “Need for 
hospitalization due to worsening of depression” or “Need for alternative treatment for 
depressive symptoms”) or the dates of the corresponding MADRS or CGI-S assessments. 
For the relapses based on MADRS total score ≥ 18 at 2 consecutive visits, the relapse 
date is defined as the assessment date of the first visit of the 2 consecutive assessments.  
14.4 
REPEATED OR UNSCHEDULED ASSESSMENTS OF SAFETY 
PARAMETERS 
If end-of-study assessments are repeated or if unscheduled visits occur, the last non-
missing postbaseline assessment will be used as the end-of-study assessment for 
generating summary statistics. However, all postbaseline assessments will be used for 
PCS value determinations, and all assessments will be presented in the data listings. 
14.5 
MISSING SEVERITY ASSESSMENT FOR ADVERSE EVENTS 
If severity is missing for an AE that started before the date of the first dose of open-label 
IP, an intensity of mild will be assigned. If severity is missing for an AE that started on or 
after the date of the first dose of open-label IP, a severity of severe will be assigned. The 
imputed values for severity assessment will be used for the incidence summary; the 
values will be shown as missing in the data listings. 
14.6 
MISSING CAUSAL RELATIONSHIP TO STUDY DRUG FOR 
ADVERSE EVENTS 
If the causal relationship to the IP is missing for an AE that started on or after the date of 
the first dose of open-label IP, a causality of yes will be assigned. The imputed values for 
causal relationship to randomized treatment will be used for the incidence summary; the 
values will be shown as missing in the data listings. 
14.7 
MISSING DATE INFORMATION FOR ADVERSE EVENTS 
The following imputation rules only apply to cases in which the start date for an AE is 
incomplete (ie, partly missing). 


Allergan PLC 
 
Page 39 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
Missing month and day 
 If the year of the incomplete start date is the same as the year of the first dose of 
open-label IP, the month and day of the first dose of open-label IP will be assigned to 
the missing fields. 
 If the year of the incomplete start date is before the year of the first dose of open-label 
IP, 31 Dec will be assigned to the missing fields. 
 If the year of the incomplete start date is after the year of the first dose of open-label 
IP, 01 Jan will be assigned to the missing fields. 
Missing month only 
 If only the month is missing, the day will be treated as missing and both the month 
and the day will be replaced according to the above procedure. 
Missing day only 
 If the month and year of the incomplete start date are the same as the month and year 
of the first dose of open-label IP, the day of the first dose of open-label IP will be 
assigned to the missing day. 
 If either the year of the incomplete start date is before the year of the date of the first 
dose of open-label IP or if both years are the same, but the month of the incomplete 
start date is before the month of the date of the first dose of open-label IP, the last day 
of the month will be assigned to the missing day. 
 If either the year of the incomplete start date is after the year of the date of the first 
dose of open-label IP or if both years are the same, but the month of the incomplete 
start date is after the month of the date of the first dose of open-label IP, the first day 
of the month will be assigned to the missing day. 
If the stop date is complete and the imputed start date as above is after the stop date, the 
start date will be imputed by the stop date. 
If the start date is completely missing and the stop date is complete, the following 
algorithm will be used to impute the start date: 
 If the stop date is after the date of the first dose of open-label IP, the date of the first 
dose of open-label IP will be assigned to the missing start date. 
 If the stop date is before the date of the first dose of open-label IP, the stop date will 
be assigned to the missing start date. 


Allergan PLC 
 
Page 40 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
14.8 
MISSING DATE INFORMATION FOR PRIOR OR 
CONCOMITANT MEDICATIONS 
For prior or concomitant medications, including background ADT, incomplete 
(i.e. partially missing) start dates and/or stop dates will be imputed. When the start date 
and the stop date are both incomplete for a patient, the start date will be imputed first.  
14.8.1 
Incomplete Start Date 
The following rules will be applied to impute the missing numeric fields for an 
incomplete prior or concomitant medication start date. If the stop date is complete (or 
imputed) and the imputed start date is after the stop date, the start date will be imputed 
using the stop date. 
Missing month and day 
 If the year of the incomplete start date is the same as the year of the first dose of 
open-label IP, the month and day of the first dose of open-label IP will be assigned to 
the missing fields. 
 If the year of the incomplete start date is before the year of the first dose of open-label 
IP, 31 Dec will be assigned to the missing fields. 
 If the year of the incomplete start date is after the year of the first dose of open-label 
IP, 01 Jan will be assigned to the missing fields. 
Missing month only 
 If only the month is missing, the day will be treated as missing and both the month 
and the day will be replaced according to the above procedure. 
Missing day only 
 If the month and year of the incomplete start date are the same as the month and year 
of the first dose of open-label IP, the day of the first dose of open-label IP will be 
assigned to the missing day. 
 If either the year of the incomplete start date is before the year of the date of the first 
dose of open-label IP or if both years are the same, but the month of the incomplete 
start date is before the month of the date of the first dose of open-label IP, the last day 
of the month will be assigned to the missing day. 


Allergan PLC 
 
Page 41 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 If either the year of the incomplete start date is after the year of the date of the first 
dose of open-label IP or if both years are the same, but the month of the incomplete 
start date is after the month of the date of the first dose of open-label IP, the first day 
of the month will be assigned to the missing day. 
14.8.2 
Incomplete Stop Date 
The following rules will be applied to impute the missing numeric fields for an 
incomplete prior or concomitant medication stop date.  If the imputed stop date is before 
the start date (imputed or non-imputed start date), the imputed stop date will be equal to 
the start date. 
Missing month and day 
 If the year of the incomplete stop date is the same as the year of the later of the date 
of the last dose of open-label IP and the date of last dose of double-blind IP, the 
month and day of the later of the date of the last dose of open-label IP and the date of 
last dose of double-blind IP will be assigned to the missing fields. 
 If the year of the incomplete stop date is before the year of the later of the date of the 
last dose of open-label IP and the date of last dose of double-blind IP, 
December 31 will be assigned to the missing fields. 
 If the year of the incomplete stop date is after the year of the later of the date of the 
last dose of open-label IP and the date of last dose of double-blind IP, January 1 will 
be assigned to the missing fields. 
Missing month only 
 If only the month is missing, the day will be treated as missing and both the month 
and the day will be replaced according to the above procedure. 
Missing day only 
 If the month and year of the incomplete stop date are the same as the month and year 
of the later of the date of the last dose of open-label IP and the date of last dose of 
double-blind IP, the day of the later of the date of the last dose of open-label IP and 
the date of last dose of double-blind IP will be assigned to the missing day. 
 If either the year of the incomplete stop date is before the year of the later of the date 
of the last dose of open-label IP and the date of last dose of double-blind IP or if both 
years are the same but the month of the incomplete stop date is before the month of 
the date of the later of the date of the last dose of open-label IP and the date of last 
dose of double-blind IP, the last day of the month will be assigned to the missing day. 


Allergan PLC 
 
Page 42 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
 If either the year of the incomplete stop date is after the year of the date of the later of 
the date of the last dose of open-label IP and the date of last dose of double-blind IP 
or if both years are the same but the month of the incomplete stop date is after the 
month of the later of the date of the last dose of open-label IP and the date of last dose 
of double-blind IP, the first day of the month will be assigned to the missing day. 


Allergan PLC 
 
Page 43 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
14.10 
ACTUAL TREATMENT FOR ANALYSIS 
If a wrong kit was administered to a patient, the treatment to which a patient was 
randomized will be used for all the analyses.   
14.11 
STRATIFICATION HANDLING CONVENTIONS 
Stratification is not being implemented in this study. 
 


Allergan PLC 
 
Page 44 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019 
15.0 
CHANGES TO ANALYSES SPECIFIED IN PROTOCOL 
Analyses and output have been limited to those needed to support the writing of an 
abbreviated CSR.  The major changes to the analyses specified in the original protocol, 
dated 02MAY2018, are as follows: 
 The primary efficacy analysis will be performed via the Kaplan-Meier curve for the 
cumulative distribution function of time to relapse for each treatment group.  
 
 
 
 
 
 
 
 


Allergan PLC 
 
Page 45 
Rapastinel 
RAP-MD-33 Statistical Analysis Plan 
 
26 August 2019